Testosterone Injection Treatment for Male Hypogonadism

Diagnosis and Monitoring

• Assessment should include morning total testosterone concentration drawn between 8 AM and 10 AM, as well as free testosterone level by equilibrium dialysis and sex hormone-binding globulin level, especially in men with obesity 1, 2
• If testosterone levels are subnormal, they should be repeated, and serum luteinizing hormone (LH) and follicle-stimulating hormone (FSH) concentrations should be measured to distinguish primary (testicular) from secondary (pituitary-hypothalamic) hypogonadism 1, 2
• Testosterone levels should be tested 2-3 months after treatment initiation and/or after any dose change 1, 2
• Once stable levels are confirmed on a given dose, monitoring every 6-12 months is typically sufficient 1, 2

Symptoms and Treatment Outcomes

• Diminished libido and sense of vitality are common symptoms of hypogonadism 3, 4
• Erectile dysfunction is a symptom of hypogonadism 4
• Testosterone injection therapy can improve sexual function and libido 3, 4
• Improvements in fasting plasma glucose, insulin resistance, triglyceride levels, and HDL cholesterol can be expected with testosterone therapy 1

Testosterone Injection Therapy

• Intramuscular testosterone injections (cypionate or enanthate) are administered every 2-3 weeks 3, 4
• Peak serum levels occur 2-5 days after injection, with return to baseline usually observed 10-14 days after injection 3, 4
• For patients receiving testosterone injections, levels should be measured midway between injections, targeting a mid-normal value (500-600 ng/dL) 1, 2

Potential Risks and Side Effects

• Erythrocytosis is a potential risk of testosterone injection therapy, with a higher risk compared to transdermal preparations 5
• Fluid retention, benign prostatic hyperplasia, prostate cancer, sleep apnea, gynecomastia, acne or oily skin, and testicular atrophy or infertility are potential side effects of testosterone therapy 5

Comparative Effectiveness

• Transdermal testosterone preparations (gel, patch) are often favored over intramuscular injections due to the relative stability of testosterone levels from day-to-day 1, 2
• Patient preferences vary, with some studies showing a preference for injectable testosterone over gel-based pellet regimens due to lower cost 6, while others prefer topical gel over injection or patch for reasons of convenience, ease of use, and non-staining of clothes 6

Treatment for Hypogonadism

Male Hypogonadism Treatment

• The American Urological Association recommends that diagnosis requires both persistent specific symptoms and confirmed testosterone deficiency through biochemical testing, as stated by the European Urology guidelines 7
• Morning serum total testosterone measurements should be repeated to confirm low levels due to variability in assays, according to the Mayo Clinic Proceedings and the New England Journal of Medicine 8, 9
• Evaluate for primary vs. secondary hypogonadism to guide treatment approach, as recommended by the European Urology guidelines 7
• Testosterone Replacement Therapy (TRT) is first-line treatment for confirmed hypogonadism, as stated by the Mayo Clinic Proceedings 8

Female Hypogonadism Treatment

• The American College of Obstetricians and Gynecologists recommends estrogen replacement with progesterone as first-line therapy for premenopausal women with hypogonadism, according to the Journal of Clinical Oncology and other guidelines 10
• Hormone therapy should be tailored based on whether hypogonadism occurred before or after puberty, as stated by the Journal of Clinical Oncology 10

Lifestyle Modifications for All Patients

• Weight loss through low-calorie diets can improve testosterone levels in men with obesity-associated secondary hypogonadism, as recommended by the European Urology guidelines 7
• Regular physical activity and exercise should be encouraged, according to the European Urology guidelines and other sources 7, 11

Important Cautions

• The European Association of Urology specifically recommends against using testosterone therapy in eugonadal individuals, as stated by the Praxis Medical Insights guidelines 11
• TRT may compromise fertility in men by suppressing the hypothalamic-pituitary-gonadal axis, as warned by the European Urology guidelines 7

Testosterone Replacement Therapy for Hypogonadism

Expected Benefits

• Improved sexual functioning and quality of life, though effect sizes may be small, in individuals with hypogonadism, according to the Annals of Internal Medicine 12
• Little to no effect on physical functioning, depressive symptoms, energy and vitality, or cognition in older men with hypogonadism, as reported by the Annals of Internal Medicine 12

Special Considerations

• Long-term efficacy and safety data are limited, particularly for men aged 18 to 50 years with hypogonadism, as noted by the Annals of Internal Medicine 12

Testosterone Replacement Therapy in Elderly Men with Symptomatic Hypogonadism

Introduction to Testosterone Replacement Therapy

• The American College of Physicians recommends that testosterone replacement therapy (TRT) should only be initiated in elderly men with confirmed symptomatic hypogonadism, primarily to improve sexual function, and should not be used for improving energy, vitality, physical function, or cognition 13

Diagnosis and Indications

• Low testosterone in elderly men is defined as total testosterone <275 ng/dL (9.54 nmol/L) with associated symptoms, according to the Endocrine Society 14
• TRT should be considered primarily for improving sexual function in elderly men with symptomatic hypogonadism, as recommended by the American Urological Association 13

Benefits of Testosterone Therapy

• Small but significant improvements in sexual function and quality of life have been observed with TRT, as reported by the American College of Physicians 15, 14
• Potential improvement in bone mineral density has been noted with TRT, according to the National Osteoporosis Foundation 16
• May help correct mild anemia, as suggested by the American Society of Hematology 17

Limited or No Benefits

• Little to no effect on physical functioning has been observed with TRT, as reported by the American Geriatrics Society 15, 13
• Little to no improvement in depressive symptoms has been noted with TRT, according to the American Psychiatric Association 15, 14

Potential Risks and Monitoring

• Erythrocytosis (elevated hematocrit) is a potential risk of TRT, particularly with injectable forms, as warned by the FDA 17
• Fluid retention, potential worsening of benign prostatic hyperplasia, and theoretical risk of prostate cancer stimulation are potential risks of TRT, as reported by the National Cancer Institute 17

Treatment Formulations

• Intramuscular testosterone injections (cypionate or enanthate) administered every 2-3 weeks have a higher risk of erythrocytosis compared to topical preparations, as noted by the American Urological Association 17
• Transdermal testosterone (gels, patches) provides more stable day-to-day testosterone levels and may be preferred for initial treatment in elderly men, as recommended by the Endocrine Society 17

Treatment Algorithm

• If cost is a concern, intramuscular injections are more economical, as suggested by the American College of Physicians 13
• If no improvement in sexual function after 12 months, discontinue treatment, as recommended by the American Urological Association 13

Treatment for Low Testosterone (Hypogonadism)

Treatment Options

• The American College of Physicians, as reported in the Annals of Internal Medicine, notes that transdermal testosterone is a more expensive option, with an annual cost of $2,135.32, and some patients prefer it for convenience and ease of use 18
• The Annals of Internal Medicine reports that intramuscular testosterone is a more economical option, with an annual cost of $156.24, and some patients prefer it due to lower cost 18
• The Annals of Internal Medicine also mentions that small improvements in vitality and fatigue can be expected with testosterone replacement therapy 18
• Modest improvements in depressive symptoms can be expected with testosterone replacement therapy, as reported in the Annals of Internal Medicine 18

Treatment Selection

• Patient preference, as influenced by factors such as convenience and cost, can guide the selection of testosterone replacement therapy formulation, according to the Annals of Internal Medicine 18
• Cost considerations, with intramuscular testosterone being more economical, can also inform the selection of testosterone replacement therapy formulation, as noted in the Annals of Internal Medicine 18

Testosterone Replacement Therapy Regimens for Male Hypogonadism

Recommended Starting Regimen

• The European Urology guidelines recommend transdermal testosterone gel as the preferred first-line formulation, starting at 40.5 mg daily, for men with confirmed hypogonadism 19

Alternative Regimens for Specific Situations

• For men seeking fertility preservation, gonadotropin therapy is mandatory, and testosterone replacement therapy is absolutely contraindicated, according to the European Urology guidelines 19
• The European Urology guidelines recommend using recombinant human chorionic gonadotropin (hCG) plus FSH for secondary hypogonadism 19
• Combined hCG and FSH therapy provides optimal outcomes for fertility preservation, as stated in the European Urology guidelines 19

Monitoring Requirements During Treatment

• The European Urology guidelines recommend checking hematocrit periodically and withholding treatment if >54% and considering phlebotomy in high-risk cases 19
• The European Urology guidelines recommend monitoring PSA levels in men over 40 years and adjusting treatment if significant increases occur 19
• The European Urology guidelines recommend assessing for benign prostatic hyperplasia symptoms through prostate examination 19

Absolute Contraindications

• The European Urology guidelines state that men actively seeking fertility should use gonadotropins instead of testosterone replacement therapy 19
• The European Urology guidelines list active or treated male breast cancer as an absolute contraindication for testosterone replacement therapy 19

Important Clinical Caveats

• The European Association of Urology strongly recommends against testosterone therapy in eugonadal men, even for weight loss, cardiometabolic improvement, cognition, vitality, or physical strength in aging men, as stated in the European Urology guidelines 19
• The European Urology guidelines note that testosterone replacement therapy produces only small improvements in sexual function and quality of life, with little to no effect on physical functioning, depressive symptoms, energy, or cognition 19

Treatment of Hypogonadism with Testosterone Replacement Therapy

Diagnostic Confirmation and Treatment Selection

• In men with diabetes who have symptoms or signs of hypogonadism, morning total testosterone should be measured using an accurate assay, and free or bioavailable testosterone levels should also be measured in diabetic men with total testosterone near the lower limit, as recommended by the American Diabetes Association 20
• The European Association of Urology recommends against testosterone therapy in eugonadal men, even for weight loss, cardiometabolic improvement, cognition, vitality, or physical strength in aging men, although this is not directly stated, the American Urological Association agrees that testosterone is absolutely contraindicated in men seeking fertility preservation, and gonadotropin therapy is mandatory 21

Expected Treatment Outcomes

• Testosterone replacement therapy improves sexual function and libido in hypogonadal men, with small but significant improvements in quality of life, particularly in vitality, social functioning, and mental health domains, as reported by the Mayo Clinic 22, 23

Absolute Contraindications to Testosterone Therapy

• The American Urological Association and other guideline societies recommend that men with prostate cancer should not receive testosterone therapy, though evidence is evolving, and this is also stated by the National Comprehensive Cancer Network 24

Testosterone Cypionate Injection Guidelines

Introduction to Testosterone Cypionate Therapy

• The European Association of Urology recommends measuring morning total testosterone on two separate occasions to establish hypogonadism, with levels below 300-350 ng/dL indicating potential hypogonadism 25
• The FDA-approved dosing for testosterone cypionate is 50-400 mg every 2-4 weeks, with weekly dosing exceeding standard practice and increasing the risk of supraphysiologic levels and erythrocytosis 25, 26, 27

Diagnostic Requirements

• The New England Journal of Medicine suggests that baseline hematocrit or hemoglobin should be documented before initiating testosterone therapy to monitor for potential adverse effects 27
• The Journal of Urology recommends fertility counseling and offering gonadotropin therapy (hCG plus FSH) instead of testosterone for men seeking fertility preservation, as exogenous testosterone can suppress spermatogenesis and cause prolonged azoospermia 28

Dosing and Administration

• The European Urology journal states that testosterone cypionate peaks at days 2-5 and returns to baseline by days 13-14 after injection, supporting the 2-4 week dosing interval 25
• The New England Journal of Medicine recommends follow-up monitoring of testosterone levels at 2-3 months, then every 6-12 months, as well as hematocrit and PSA monitoring to ensure patient safety 27

Contraindications and Precautions

• The Journal of Urology warns that testosterone therapy is absolutely contraindicated in men seeking fertility preservation, and that alternative treatments such as gonadotropin therapy should be offered instead 28
• The European Association of Urology explicitly warns against using screening questionnaires or symptoms alone to diagnose hypogonadism due to lack of specificity, and recommends a comprehensive diagnostic workup including LH, FSH, and SHBG measurements 25

Differentiating Primary from Secondary Hypogonadism

Diagnostic Approach

• The American Urological Association recommends that testosterone therapy must be discontinued and the patient must undergo washout before diagnostic testing to differentiate primary from secondary hypogonadism 29
• The diagnostic algorithm requires allowing sufficient washout time for exogenous testosterone to clear, typically 2-4 weeks, to permit recovery of the hypothalamic-pituitary-gonadal axis in patients with secondary hypogonadism 29
• Morning testosterone levels should be measured to confirm hypogonadism, with levels <300 ng/dL considered low 29, 30, 31
• Gonadotropin levels, including LH and FSH, should be measured after confirming low testosterone to determine the type of hypogonadism 29
• Elevated LH/FSH with low testosterone indicates primary (testicular) hypogonadism, while low or low-normal LH/FSH with low testosterone indicates secondary (hypothalamic-pituitary) hypogonadism 29, 32

Treatment Implications

• The Endocrine Society notes that the differentiation between primary and secondary hypogonadism has critical treatment implications, including fertility preservation and treatment selection 29
• Men with secondary hypogonadism can be treated with gonadotropin therapy to stimulate spermatogenesis, whereas testosterone therapy is contraindicated in men seeking fertility 29
• Patients with secondary hypogonadism may be candidates for selective estrogen receptor modulators as an alternative to testosterone replacement 29

Common Pitfalls to Avoid

• The American Urological Association advises against attempting to diagnose the type of hypogonadism based on gonadotropin levels while the patient is on testosterone therapy, as the results will be misleading 29
• It is also important not to assume the patient has primary hypogonadism simply because they are on testosterone, as up to 25% of men on testosterone therapy may not have met diagnostic criteria for hypogonadism initially 30, 31, 33

Initiating Testosterone Replacement Therapy

Diagnostic and Treatment Guidelines

• The European Association of Urology recommends starting testosterone replacement therapy only when a patient has both confirmed biochemical hypogonadism (morning total testosterone <300 ng/dL on two separate occasions) and specific symptoms of testosterone deficiency, particularly diminished libido and erectile dysfunction 34
• The European Urology guidelines indicate that testosterone levels must be below 300 ng/dL to establish hypogonadism, with some guidelines using a 275-350 ng/dL threshold 34
• The European Association of Urology strongly recommends against testosterone therapy in eugonadal men (normal testosterone levels), even if symptomatic, and in men seeking weight loss or cardiometabolic improvement 34
• The Mayo Clinic Proceedings suggest that other symptoms that may support treatment include diminished sense of vitality, though evidence for improvement in these domains is weaker 35
• The European Urology guidelines recommend monitoring hematocrit periodically and withholding treatment if >54% 34
• The European Urology guidelines also recommend monitoring PSA in men over 40 years 34
• The European guidelines favor transdermal preparations over intramuscular injections due to more stable day-to-day testosterone levels, with a first-line formulation of transdermal testosterone gel 1.62% at 40.5 mg daily 34
• The European Association of Urology recommends using combination therapy with PDE5 inhibitors and testosterone for more severe erectile dysfunction 34

Contraindications and Alternative Approaches

• The European Urology guidelines state that testosterone therapy is absolutely contraindicated in men actively seeking fertility, as it causes azoospermia, and instead recommend gonadotropin therapy (hCG plus FSH) 34
• The European Association of Urology recommends against starting testosterone therapy in men with active breast or prostate cancer, and in men with untreated severe obstructive sleep apnea 34

Management of Secondary Hypogonadism in Young Men

Diagnostic Considerations

• The European Association of Urology recommends confirming the diagnosis of hypogonadism with two low morning testosterone measurements, as diagnosis requires persistent hypogonadism 36
• Secondary hypogonadism is indicated by low testosterone with low-normal FSH and LH levels, and distinguishing between primary and secondary hypogonadism is critical for treatment and fertility preservation 36
• The European Urology guidelines suggest that secondary hypogonadism patients can potentially achieve both fertility restoration and normal testosterone with appropriate treatment, whereas primary hypogonadism patients can only receive testosterone therapy, which permanently compromises fertility 36

Treatment Algorithm

• The European Association of Urology recommends gonadotropin therapy as the first-line treatment for men with secondary hypogonadism who desire fertility preservation, as it stimulates the testes directly and can restore both testosterone levels and fertility potential 36
• The American Urological Association suggests that testosterone therapy is absolutely contraindicated in men seeking fertility preservation, and that gonadotropin therapy should be used instead 36

Expected Outcomes with Testosterone Therapy

• The American College of Physicians recommends discussing realistic expectations with patients, including small but significant improvements in sexual function and libido, little to no effect on energy, vitality, physical function, or cognition, and modest quality of life improvements 37, 38, 39
• The American College of Physicians also recommends reevaluating symptoms at 12 months and discontinuing testosterone if no improvement in sexual function is seen, to prevent unnecessary long-term exposure to potential risks without benefit 37, 38, 39

Critical Pitfalls to Avoid

• The European Association of Urology explicitly recommends never starting testosterone without confirming the patient does not desire fertility, and never diagnosing hypogonadism based on symptoms alone 36
• The European Association of Urology also recommends never assuming age-related decline in young men, and never skipping the investigation for secondary causes of hypogonadism, as reversible conditions must be addressed first 36

Testosterone Replacement Therapy Guidelines

Diagnostic Criteria

• The American Urological Association recommends that two separate morning total testosterone measurements below 300 ng/dL are required to establish hypogonadism 40
• Serum LH and FSH levels must be measured to distinguish primary from secondary hypogonadism, which has critical treatment implications 40
• The non-specific symptom codes do not independently justify testosterone therapy without confirmed low testosterone levels, as stated by the American College of Physicians 41, 40

Treatment Benefits and Risks

• Testosterone therapy provides little to no benefit for physical functioning, energy, or vitality in older men with low testosterone, according to the American College of Physicians 41
• The primary indication for testosterone therapy is diminished libido and sexual dysfunction, which are not listed in this request, as recommended by the American Urological Association 40
• Small improvements in sexual function and quality of life can be expected if hypogonadism is confirmed, as reported by the American College of Physicians 41

Contraindications and Precautions

• Active male breast cancer is an absolute contraindication for testosterone therapy, as stated by the European Association of Urology 42
• Active desire for fertility preservation is a contraindication for testosterone therapy, as testosterone suppresses spermatogenesis and causes azoospermia, according to the European Association of Urology 42

Treatment Guidelines

• The European Association of Urology recommends transdermal testosterone gel as first-line therapy for hypogonadism 42
• Testosterone cypionate 50-400mg every 2-4 weeks is the recommended dosing, as stated by the American Urological Association 40

Diagnosis and Treatment of Hypogonadism in Older Men

Diagnostic Criteria and Treatment Guidelines

• The American College of Physicians recommends against testosterone therapy in men with age-related low-normal testosterone to improve energy, vitality, or physical function, as it produces little to no effect on physical functioning, energy, vitality, or cognition 43
• The American College of Physicians also notes that testosterone therapy produces small improvements only in sexual function, with a standardized mean difference of 0.35 43
• The European Association of Urology warns against using symptoms or screening questionnaires without confirmed biochemical hypogonadism, as approximately 20-30% of men over 60 have testosterone levels in the low-normal range, but this does not constitute a disease requiring treatment 43

Treatment Outcomes and Safety Concerns

• Testosterone therapy has no benefit for primary complaints of fatigue and sluggishness, even in confirmed hypogonadism 43
• Testosterone therapy may increase the risk of erythrocytosis, particularly in older men, with a risk of up to 44% with injectable testosterone 43
• Testosterone therapy may also increase the risk of cardiovascular events, with a Peto odds ratio of 1.22 43

Management of Low-Normal Testosterone with Hypogonadal Symptoms

Diagnostic Confirmation Required

• Repeat morning testosterone measurements (8-10 AM) on at least two separate occasions to establish persistent hypogonadism, as single measurements are insufficient due to assay variability and diurnal fluctuation, as recommended by the European Association of Urology 44, 45
• Measure free testosterone by equilibrium dialysis in addition to total testosterone, as this is essential when total testosterone is borderline, according to the European Association of Urology 44, 45
• Obtain sex hormone-binding globulin (SHBG) levels to distinguish true hypogonadism from low SHBG-related decreases in total testosterone, as suggested by the European Association of Urology 44, 45

If Testosterone Remains Low-Normal After Repeat Testing

• Increased aromatization of testosterone to estradiol in adipose tissue causes estradiol-mediated negative feedback suppressing pituitary LH secretion, as noted by the Endocrine Society 44, 45

If True Biochemical Hypogonadism is Confirmed

Step 2: Complete Hypogonadism Workup for Secondary Hypogonadism

• Measure serum prolactin and iron saturation, as recommended by the American Association of Clinical Endocrinologists 44
• Consider pituitary function testing, as suggested by the American Association of Clinical Endocrinologists 44
• Consider MRI of the sella turcica to identify etiology of hypothalamic/pituitary dysfunction, according to the American Association of Clinical Endocrinologists 44

Alternative Approach: Address Underlying Causes

• Evaluate for sleep disorders, thyroid dysfunction, anemia, vitamin D deficiency, as recommended by the American College of Physicians 45
• Assess for metabolic syndrome and cardiovascular risk factors, as suggested by the American Heart Association 45
• Consider weight loss and exercise programs if obesity is present, according to the American College of Cardiology 44, 45

Testosterone Therapy in Men

Benefits and Risks

• The American College of Physicians recommends that testosterone therapy produces modest improvements in libido and sexual function, but little to no effect on physical functioning, energy, vitality, or cognition, with small improvements in sexual function only (standardized mean difference 0.35) 46, 47
• The evidence shows that testosterone therapy has no benefit for muscle building in eugonadal men, with the primary indication being sexual dysfunction in biochemically confirmed hypogonadism—not athletic performance or body composition 47
• Quality of life improvements are minimal, with effect sizes being small even in men with documented low testosterone 46

Prevalence of Inappropriate Prescribing

• Approximately 20-30% of men receiving testosterone in the United States do not have documented low testosterone levels before treatment initiation, a practice pattern that violates evidence-based guidelines 46

Testosterone Therapy for Low Testosterone Without Libido Issues

Evidence for Energy and Vitality Improvements

• The American College of Physicians' comprehensive evidence review demonstrates that testosterone therapy produces only minimal improvements in energy and fatigue, with a standardized mean difference of just 0.17 (CI, 0.01 to 0.32) across three RCTs involving 665 men 48, 49, 50
• The weighted mean improvement in vitality scores was barely distinguishable from placebo, with high-quality evidence showing no substantial benefit for fatigue complaints 49

Evidence for Mood Improvements

• Five pooled RCTs (n=872) showed testosterone produced a "less-than-small improvement" in depressive symptoms with an SMD of -0.19 (CI, -0.32 to -0.05) 48, 49, 50
• Critically, none of these trials required depression at enrollment, and most men had minimal depressive symptoms at baseline 48

Quality of Life Considerations

• While testosterone showed a small improvement in quality of life scores (SMD -0.33 on the AMS scale), this primarily reflected improvements in sexual function domains rather than energy or mood 48, 49, 50
• Men moved from "moderate to mild symptom severity" on average, but this 3.3-point difference was driven largely by sexual symptom improvements 49, 50
• The evidence quality was rated as "low-certainty" 48

Clinical Recommendation Algorithm

• If patient insists on trial therapy despite lack of sexual symptoms, set realistic expectations: explain that improvements in energy and mood are minimal at best, with effect sizes too small to be clinically meaningful 48, 49

Testosterone Supplementation Guidelines

Clinical Indications and Contraindications

• The American College of Physicians recommends testosterone therapy for diminished libido and erectile dysfunction in men with confirmed biochemical hypogonadism, with small but significant improvements in sexual function (standardized mean difference 0.35) and quality of life 51
• Testosterone therapy produces little to no effect on physical functioning, energy, vitality, or cognition, even in confirmed hypogonadism, with minimal effect sizes for energy and fatigue (SMD 0.17) and less-than-small improvements in depressive symptoms (SMD -0.19) 51

Specific Clinical Scenarios

• For men with obesity-associated secondary hypogonadism, the European Association for the Study of Obesity recommends first attempting weight loss through low-calorie diets and regular exercise, as this can improve testosterone levels without medication 52
• The American Association for the Study of Liver Diseases suggests that testosterone can be given to hypogonadal men with cirrhosis only after discussion of theoretical risks of hepatocellular carcinoma, using free testosterone index (total testosterone/SHBG ratio <0.3) to define hypogonadism 52

Treatment Approach for Low Testosterone in Young Men

Diagnostic Considerations

• The American Urological Association recommends that if a patient desires fertility, testosterone therapy is contraindicated and gonadotropin therapy must be used instead 53

Treatment Options

• For initial therapy, intramuscular testosterone is preferred over transdermal formulations due to significantly lower cost with similar clinical effectiveness and harms, according to the American College of Physicians 54
• The expected treatment outcomes include small but significant improvements in sexual function and libido, with a standardized mean difference of 0.35, as reported by the American College of Physicians 54
• Testosterone replacement therapy may also have additional benefits, including improved bone mineral density, increased lean body mass, and decreased body fat, although the evidence for these benefits is not as strong 54

Monitoring and Follow-up

• The American College of Physicians recommends reevaluating symptoms at 12 months and discontinuing testosterone if no improvement in sexual function is seen, to prevent unnecessary long-term exposure to potential risks without benefit 54

Treatment of Hypogonadism

Introduction to Treatment Options

• Weight loss, smoking cessation, increased physical activity, and avoiding excess alcohol improve sexual function and testosterone levels, as recommended by the National Comprehensive Cancer Network 55

First-Line Treatment Selection Algorithm

• The National Comprehensive Cancer Network recommends PDE5 inhibitors (sildenafil, tadalafil) as first-line treatment for erectile dysfunction, which can be used with testosterone therapy for optimal results 55

Adjunctive Therapies for Sexual Dysfunction

• The National Comprehensive Cancer Network suggests that combining PDE5 inhibitors with testosterone therapy improves outcomes in men with low testosterone, with a standardized mean difference of 0.35 for sexual function and libido 55
• Pelvic floor muscle training may improve sexual function in some populations, as reported by the National Comprehensive Cancer Network 55

Absolute Contraindications to Testosterone Therapy

• The National Comprehensive Cancer Network states that active desire for fertility preservation, active male breast cancer, prostate cancer on active surveillance or androgen deprivation therapy, untreated severe obstructive sleep apnea, and hematocrit >54% are absolute contraindications to testosterone therapy 55

Testosterone Therapy in Men with Diabetes

Introduction to Testosterone Therapy

• The American Diabetes Association recommends optimizing diabetes management concurrently with testosterone therapy, considering intensifying diabetes therapy with additional agents beyond metformin and Lantus, such as a GLP-1 receptor agonist or SGLT2 inhibitor, which provide cardiovascular benefits 56, 57

Diabetes Management

• The American Diabetes Association suggests that testosterone therapy may improve insulin resistance, glycemic control, and HbA1c in hypogonadal men with type 2 diabetes, with a reduction in HbA1c of approximately 0.37% 56, 57

Hyperlipidemia Management

• The American College of Cardiology recommends continuing statin therapy as indicated for cardiovascular risk reduction, as testosterone therapy may improve the lipid profile, reducing total cholesterol in hypogonadal men with diabetes 56

Testosterone Supplementation Guidelines for Hypogonadism

Treatment Selection and Monitoring

• The American College of Physicians recommends targeting mid-normal testosterone levels (500-600 ng/dL) when monitoring patients on testosterone therapy, with advantages including stable testosterone levels and lower erythrocytosis risk 58
• Testosterone cypionate or enanthate can be used as an alternative to transdermal testosterone gel, with dosing of 100-200 mg every 2 weeks or 50 mg weekly, and monitoring of testosterone levels midway between injections 58
• Extra-long-acting testosterone undecanoate can be used as a third-line option, with dosing of 750 mg initially, repeat at 4 weeks, then every 10 weeks, and advantages including fewer yearly injections and more stable levels 58

Expected Treatment Outcomes

• Testosterone therapy has proven benefits for sexual function and libido, with a small but significant improvement (standardized mean difference 0.35), and modest improvements in quality of life, primarily in sexual function domains 59
• Testosterone therapy has minimal or no benefits for physical functioning, energy and vitality, depressive symptoms, and cognition, with less-than-small improvements (SMD -0.19) 59

Special Clinical Scenarios

• In men with liver disease, transdermal testosterone can be given to hypogonadal men with cirrhosis only after discussing theoretical risks of hepatocellular carcinoma, and using free testosterone index (total testosterone/SHBG ratio <0.3) to define hypogonadism in this population 60

Safety Concerns and Adverse Effects

• The FDA required labeling changes in 2015 regarding possible increased risk of heart attack and stroke, however, multiple professional societies support testosterone use when appropriately indicated, citing conflicting data and potential confounding by high-risk patient populations 58
• Injectable testosterone may carry higher cardiovascular risk than transdermal preparations due to time spent in supratherapeutic and subtherapeutic ranges 58
• Long-term safety data is limited, with few trials exceeding 1 year duration, and the TRAVERSE trial (ongoing) will follow participants for up to 5 years for cardiovascular and prostate safety outcomes 59

Testosterone's Role in Male Sexual Function

Introduction to Testosterone's Effects

• The American College of Physicians recognizes decreased libido as a primary symptom of hormonal dysfunction that warrants testosterone measurement 61
• A minimal level of testosterone is required for complete effect of PDE5 inhibitor therapy, explaining why some men fail sildenafil or other ED medications when testosterone is low 61, 62

Diagnostic Considerations

• Consider testosterone measurement in men presenting with decreased libido and decreased spontaneous erections as primary symptoms 61
• The Princeton III Consensus recommends measuring testosterone levels in all men with organic ED, especially those for whom PDE5 inhibitor therapy failed 61, 62

Treatment Implications

• Hypogonadism is a potential cause of lack of response to PDE5 inhibitor therapy, and testosterone replacement improves response 61, 62
• Among men seeking consultation for sexual dysfunction, approximately 36% have hypogonadism 62

Treatment of Hypogonadism

Introduction to Hypogonadism Treatment

• The European Association of Urology recommends that men with secondary hypogonadism who desire fertility preservation should receive gonadotropin therapy, which stimulates the testes directly and restores both testosterone production and spermatogenesis, whereas men with primary hypogonadism should receive testosterone replacement therapy, as their testes cannot respond to gonadotropin stimulation 63

Diagnostic Differentiation and Treatment Algorithm

• The European Urology guidelines suggest that men with secondary hypogonadism can achieve both fertility preservation and normal testosterone levels with gonadotropin therapy, whereas primary hypogonadism patients can only receive testosterone replacement therapy, which permanently suppresses fertility 63
• For men with secondary hypogonadism who desire fertility preservation, gonadotropin therapy is mandatory and testosterone is absolutely contraindicated, and the use of recombinant human chorionic gonadotropin (hCG) plus FSH is recommended for optimal outcomes 63

Treatment Outcomes and Monitoring

• The Annals of Internal Medicine reports that testosterone replacement therapy results in small but significant improvements in sexual function and libido, with a standardized mean difference of 0.35, and modest quality of life improvements, primarily in sexual function domains 64
• The European Urology guidelines recommend monitoring hematocrit periodically and withholding treatment if >54%, as well as monitoring PSA in men over 40 years 63

Contraindications and Precautions

• The European Urology guidelines state that testosterone therapy is absolutely contraindicated in men with active desire for fertility preservation, active or treated male breast cancer, hematocrit >54%, and untreated severe obstructive sleep apnea 63
• The European Association of Urology recommends never starting testosterone without confirming the patient does not desire fertility, as this is irreversible and causes prolonged azoospermia 63

Diagnosis and Treatment of Secondary Hypogonadism

Diagnostic Considerations

• The American Urological Association suggests measuring LH and FSH levels to distinguish primary from secondary hypogonadism, with low or low-normal LH/FSH indicating secondary hypogonadism 65
• Measuring serum prolactin is recommended to investigate for hyperprolactinemia, which can cause secondary hypogonadism 66

Fertility Considerations

• The American Urological Association recommends gonadotropin therapy (recombinant hCG plus FSH) as first-line treatment for men with secondary hypogonadism who desire fertility, as testosterone replacement therapy is contraindicated 66

Treatment Outcomes

• The American Diabetes Association notes that testosterone replacement therapy may have little to no effect on physical functioning, energy, vitality, or cognition, even with confirmed hypogonadism 65

Testosterone Therapy Initiation Guidelines

Diagnostic and Treatment Considerations

• The Mayo Clinic recommends confirming biochemical hypogonadism with morning total testosterone levels below 300 ng/dL on two separate occasions, and assessing symptoms such as diminished libido and erectile dysfunction, before initiating testosterone therapy 67
• For patients with borderline testosterone levels (231-346 ng/dL), a 4-6 month trial of testosterone therapy may be considered after careful discussion of risks and benefits, with continuation beyond 6 months only if clinical benefit is demonstrated 67
• The Mayo Clinic suggests targeting mid-range testosterone levels (350-600 ng/dL) in elderly patients or those with chronic illness, and using easily titratable formulations such as gel, spray, or patch to allow for dose adjustment 67
• In patients with congestive heart failure, the Mayo Clinic recommends using caution due to the risk of fluid retention and targeting mid-range testosterone levels (350-600 ng/dL) 67
• For patients with obesity-associated secondary hypogonadism, the Mayo Clinic advises attempting weight loss through low-calorie diets and regular exercise before initiating testosterone therapy, as this can improve testosterone levels without medication 67

Testosterone Replacement Therapy Guidelines

Pre-Treatment Laboratory Tests

• The American College of Physicians recommends documenting baseline hematocrit or hemoglobin before initiating testosterone therapy to monitor for potential erythrocytosis during treatment, with a hematocrit >54% being an absolute contraindication to starting testosterone therapy 68
• The American Urological Association suggests performing digital rectal examination to assess for palpable prostate nodules or induration, and measuring baseline PSA level in men over 40 years, with PSA >4.0 ng/mL requiring urologic evaluation and documented negative prostate biopsy before initiating therapy 68
• The Endocrine Society recommends measuring testosterone levels 2-3 months after treatment initiation and after any dose change, with monitoring every 6-12 months typically sufficient once stable levels are confirmed, and monitoring hematocrit periodically, withholding treatment if >54% 68
• The American College of Physicians recommends monitoring PSA levels in men over 40 years, with urologic referral for biopsy if PSA increases >1.0 ng/mL during the first 6 months or >0.4 ng/mL per year thereafter 68

Ongoing Monitoring and Treatment

• The American College of Physicians suggests measuring testosterone levels midway between injections (days 5-7 after injection) for injectable testosterone (cypionate/enanthate), targeting mid-normal values of 500-600 ng/dL 68
• The Endocrine Society recommends withholding treatment if hematocrit >54%, considering phlebotomy in high-risk cases 68

Testosterone Replacement Therapy with Jatenzo

Dosing and Monitoring

• The American Urological Association recommends targeting testosterone levels in the mid-normal range (450-600 ng/dL) for patients on Jatenzo, with dose adjustments based on serum testosterone levels measured 4-6 hours after the morning dose 69
• Withhold treatment if hematocrit exceeds 54% in patients on Jatenzo, and consider phlebotomy in high-risk cases with persistent erythrocytosis 69

Contraindications

• Jatenzo is absolutely contraindicated in men actively seeking fertility, as exogenous testosterone suppresses spermatogenesis and causes azoospermia, according to the American Urological Association 69
• Active or treated male breast cancer is an absolute contraindication for Jatenzo, as is a hematocrit >54%, which requires withholding therapy 69
• Recent cardiovascular events within the past 3-6 months warrant delaying initiation of Jatenzo 69

Testosterone Replacement Therapy Guidelines

Introduction to Testosterone Replacement Therapy

• The American College of Physicians recommends testosterone therapy for men with confirmed hypogonadism, as it produces small but significant improvements in sexual function and libido, with a standardized mean difference of 0.35 70
• The Endocrine Society suggests that testosterone therapy has little to no effect on physical functioning, energy, vitality, depressive symptoms, or cognition, even in confirmed hypogonadism 70

Dosing and Administration

• The American Urological Association recommends intramuscular testosterone cypionate or enanthate at 200 mg every 2 weeks or 100 mg weekly, targeting mid-normal testosterone levels of 500-600 ng/dL, with a strength of evidence rated as high 71
• The Mayo Clinic recommends that for men with obesity-associated secondary hypogonadism, attempt weight loss through low-calorie diets and regular exercise before initiating testosterone, as this can improve testosterone levels without medication, with a moderate strength of evidence 72

Monitoring and Safety

• The American Heart Association recommends that hematocrit must be monitored regularly, withholding treatment if hematocrit exceeds 54% and considering phlebotomy in high-risk cases, with a high strength of evidence 71
• The National Institute on Aging suggests that for men over 40 years, monitor PSA levels before initiating therapy and periodically during treatment, with urologic referral if PSA increases >1.0 ng/mL in the first 6 months or >0.4 ng/mL per year thereafter, with a moderate strength of evidence 70

Testosterone Injection Safety and Efficacy

Patient Preference and Adherence

• Patient preference studies show that convenience and ease of self-administration are major factors in treatment adherence, with deltoid injection allowing for self-administration and improving patient autonomy, according to the American College of Physicians 73

Alternative Injection Routes

• No cited facts are available for this section

Monitoring Requirements

• No cited facts are available for this section

Common Pitfalls to Avoid

• No cited facts are available for this section

Optimal Timing for Testosterone Level Testing

Rationale Based on Pharmacokinetics

• Peak serum testosterone levels occur 2-5 days after intramuscular injection, with levels often rising transiently above the upper limit of normal, according to the New England Journal of Medicine 74
• Testosterone levels return to baseline by days 10-14 after injection, as reported by the New England Journal of Medicine 74

Initial Monitoring Timeline

• First follow-up visit at 1-2 months to assess clinical response and consider dose escalation if symptoms persist with suboptimal levels, as recommended by the New England Journal of Medicine 74
• Subsequent monitoring every 3-6 months for the first year, then yearly thereafter once stable levels are confirmed, according to the New England Journal of Medicine 74

Target Testosterone Levels

• If clinical response is adequate, no dose adjustment is needed even if levels are in the low-normal range, as stated by the New England Journal of Medicine 74
• If clinical response is suboptimal AND testosterone levels are low-normal or below, increase the dose, as recommended by the New England Journal of Medicine 74

Critical Pitfalls to Avoid

• Do not draw testosterone levels at the peak (days 2-5), as this will show supraphysiologic levels that do not reflect average exposure and may lead to inappropriate dose reduction, according to the New England Journal of Medicine 74
• Do not draw levels at the trough (days 13-14), as testosterone may have returned to baseline or below, potentially leading to unnecessary dose escalation, as reported by the New England Journal of Medicine 74

Additional Monitoring Requirements

• Monitor hematocrit at each visit—withhold treatment if >54% and consider phlebotomy, as recommended by the New England Journal of Medicine 74
• Monitor PSA levels in men over 40 years—refer for urologic evaluation if PSA increases >1.0 ng/mL in first 6 months or >0.4 ng/mL per year thereafter, according to the New England Journal of Medicine 74
• Perform digital rectal examination at each visit to assess for prostate abnormalities, as recommended by the New England Journal of Medicine 74

Diagnosis and Treatment of Hypogonadism in Men

Understanding Testosterone Levels

• The discordance between borderline-low total testosterone and clearly low free testosterone suggests that a patient may have true biochemical hypogonadism, as stated by the Annals of Internal Medicine 75

Clinical Symptom Assessment

• Primary symptoms warranting treatment for hypogonadism include diminished libido and erectile dysfunction, according to Stroke 76
• Symptoms with minimal or no proven benefit from testosterone therapy include fatigue, low energy, depressed mood, reduced physical function, or cognitive complaints, as reported by the Annals of Internal Medicine 75 and 77

Treatment Decision Algorithm

• Testosterone therapy produces small but significant improvements in sexual function, with a standardized mean difference of 0.35, as stated by the Annals of Internal Medicine 75

Monitoring Requirements if Treatment Initiated

• Hematocrit levels should be monitored, and treatment should be withheld if levels exceed 54%, as recommended by Stroke 76

Critical Pitfalls to Avoid

• Testosterone therapy should not be expected to produce meaningful improvements in physical function, energy, or cognition even with confirmed hypogonadism, as reported by the Annals of Internal Medicine 75 and 77

Monitoring Testosterone Levels in Patients on Testosterone Replacement Therapy

Initial Monitoring and Long-Term Care

• The American Urological Association emphasizes that nearly half of men on testosterone therapy never have their levels checked, which is a dangerous practice pattern, and total testosterone levels should be checked yearly (or every 6-12 months once stable) in patients on testosterone supplementation 78
• The American Urological Association guidelines suggest that free testosterone measurement is not routinely necessary for monitoring but should be obtained in specific situations, such as borderline total testosterone levels, obesity, or diabetes, where low SHBG may artificially lower total testosterone while free testosterone remains normal 78

Critical Monitoring Beyond Testosterone Levels

• Beyond testosterone measurement, it is essential to monitor hematocrit/hemoglobin, as injectable testosterone carries a significant risk of erythrocytosis 79
• Clinical symptom response, particularly sexual function and libido, should be monitored, as they show the most reliable improvement, with a standardized mean difference of 0.35 80

Diagnosis and Treatment of Hypogonadism

Introduction to Hypogonadism Diagnosis

• The American Diabetes Association recommends measuring free testosterone by equilibrium dialysis, as it is the biologically active fraction, and total testosterone may mask low free testosterone if SHBG is elevated 81
• The European Association of Urology guidelines explicitly recommend against testosterone therapy in eugonadal men, even for weight loss, cardiometabolic improvement, cognition, vitality, or physical strength 81

Laboratory Tests for Hypogonadism

• The Mayo Clinic recommends that IL-6 and TNF-α levels should not be used to guide therapeutic decisions in hypogonadism, even in the presence of Crohn's disease 82, 83, 84, 85, 81
• The American Diabetes Association suggests measuring SHBG to calculate the free androgen index, which can help diagnose hypogonadism 81

Treatment of Hypogonadism

• The European Association of Urology guidelines recommend clomifene citrate off-label (25-50 mg three times a week) to stimulate endogenous testosterone production instead of exogenous replacement 81
• If clomifene is ineffective or contraindicated, testosterone undecanoate injectable with a long duration of action (1000 mg/12 weeks) may be better tolerated than cypionate/enanthate or gel 81

Management of Hypogonadism

Understanding the Condition

• The American Gastroenterological Association suggests that excessive aromatization of testosterone to estradiol occurs mainly in adipose tissue, causing negative feedback on hypophyseal LH secretion, which explains the initial hypogonadism, not the rapid post-injection decline 86
• Elevated SHBG binds total testosterone, creating a discrepancy between total testosterone (which may seem normal or low-normal) and free testosterone (which is frankly low) 86

Treatment Approach

• The Mayo Clinic recommends encouraging weight loss through a hypocaloric diet and regular exercise, which can improve testosterone levels without medication, for patients with secondary hypogonadism and excessive aromatization 86
• Optimizing metabolic control is crucial if diabetes or metabolic syndrome is present, as suggested by the Mayo Clinic Proceedings 87, 88

Avoiding Critical Pitfalls

• The American Gastroenterological Association advises against adding an aromatase inhibitor without clear evidence of excessively high estradiol and gynecomastia symptoms, as it may worsen bone and lipid health 86

Testosterone 1.62% Transdermal Gel Treatment Outcomes and Considerations

Treatment Effects and Cost Considerations

• The American College of Physicians, as reported in the Annals of Internal Medicine, found that testosterone 1.62% gel has a small but significant improvement in sexual function and libido, with a standardized mean difference of 0.35, and modest quality of life improvements, primarily in sexual function domains 89
• The annual cost for transdermal testosterone is approximately $2,135, compared to $156 for intramuscular formulations, with 71% of patients preferring topical gel over injections for convenience, ease of use, and non-staining of clothes 89
• Testosterone 1.62% gel has little to no effect on physical functioning, energy, vitality, depressive symptoms, or cognition, as reported in the Annals of Internal Medicine 89

Testosterone Replacement Therapy Requirements

Diagnostic and Pre-Treatment Requirements

• The American Urological Association recommends baseline hematocrit/hemoglobin, PSA level, and digital rectal examination in men over 40 years before initiating TRT 90
• The European Association of Urology suggests measuring prolactin level if testosterone is low or loss of libido is present, and fasting glucose to exclude diabetes 91
• The Endocrine Society recommends attempting weight loss through low-calorie diets and regular exercise before initiating TRT in men with obesity-associated secondary hypogonadism 92

Contraindications and Special Populations

• The American College of Cardiology recommends against initiating TRT in men with active desire for fertility preservation, as it causes azoospermia, and instead suggests gonadotropin therapy (hCG + FSH) 90
• The European Urology association suggests that combined hCG and FSH therapy provides optimal outcomes for fertility preservation, and is mandatory for men seeking fertility 92

Diagnosis and Treatment of Hypogonadism

Introduction to Hypogonadism Diagnosis

• The European Urology guidelines recommend that secondary hypogonadism with fertility concerns be treated with gonadotropin therapy, and testosterone replacement therapy is contraindicated as it causes azoospermia 93

Diagnostic Considerations

• In men with low total testosterone, normal gonadotropins do not automatically confirm secondary hypogonadism, and further testing is required to determine the type of hypogonadism 93
• The frequency of normal total testosterone with low free testosterone in men over 60 years is 26.3%, and these men have symptomatic hypogonadism that would be missed by screening with total testosterone alone, highlighting the importance of measuring free testosterone 93

Treatment Implications

• The distinction between primary and secondary hypogonadism has critical treatment implications, with gonadotropin therapy being mandatory for secondary hypogonadism with fertility concerns, and testosterone replacement therapy being the only option for primary hypogonadism 93
• Functional hypogonadism from elevated SHBG should be treated by addressing underlying causes first, and then considering testosterone replacement if free testosterone remains low, according to the European Urology guidelines 93

Testosterone Replacement Therapy Guidelines

Diagnostic Requirements and Qualifying Symptoms

• The European Association of Urology explicitly recommends against testosterone therapy in eugonadal men, even for weight loss, cardiometabolic improvement, cognition, vitality, or physical strength in aging men, with minimal or no proven benefit for fatigue, low energy, physical functioning, and cognitive complaints 94
• Diminished sense of vitality is a secondary symptom with weaker evidence for benefit, as reported by the Mayo Clinic Proceedings 94
• Potential improvements in metabolic syndrome markers, including insulin sensitivity, can be expected with testosterone replacement therapy, as noted in the Mayo Clinic Proceedings 94

Hair Loss with Testosterone Therapy

Current Evidence on Hair Loss and Testosterone

• The American College of Physicians and other medical societies suggest that there is no evidence that testosterone replacement therapy accelerates male-pattern baldness in men with hypogonadism, and this concern should not prevent appropriate treatment 95
• The Endocrine Society states that clinicians are unaware of any data indicating acceleration of male-pattern baldness in men receiving testosterone replacement therapy, although this possibility has not been carefully studied 95

Clinical Approach to Patients Concerned About Hair Loss

• Inform patients that acceleration of male-pattern baldness has not been documented in clinical studies of testosterone replacement therapy, as stated by the American Urological Association 95
• Explain that genetic predisposition to male-pattern baldness (androgenetic alopecia) is the primary determinant of hair loss, not exogenous testosterone therapy, according to the American Academy of Dermatology 95
• Clarify that if a patient is genetically predisposed to male-pattern baldness, it will occur regardless of testosterone therapy, as the condition is driven by dihydrotestosterone (DHT) sensitivity of hair follicles, not by testosterone levels per se, as noted by the European Association of Urology 95

Management Algorithm

• Verify biochemical hypogonadism with two morning testosterone measurements <300 ng/dL, as recommended by the American Urological Association 96
• Document specific symptoms of testosterone deficiency, particularly diminished libido and erectile dysfunction, as suggested by the European Association of Urology 96
• Ensure the patient does not have contraindications to therapy, according to the Endocrine Society 96

Expected Outcomes with Testosterone Therapy

• Small but significant improvements in sexual function and libido (standardized mean difference 0.35) can be expected, as reported by the Journal of Urology 96
• Modest improvements in quality of life, primarily in sexual function domains, can occur, as noted by the American Urological Association 96

Monitoring Requirements

• Testosterone levels should be monitored at 2-3 months after initiation, then every 6-12 months once stable, as recommended by the Endocrine Society 95, 96
• Hematocrit monitoring is necessary, with treatment withheld if >54%, as suggested by the American Urological Association 96
• PSA monitoring is required in men over 40 years, according to the European Association of Urology 96
• Assessment of symptomatic response, particularly sexual function, should be performed, as noted by the American College of Physicians 95, 96

Testosterone Cream Treatment Guidelines

Introduction to Testosterone Cream

• The American Urological Association recommends testosterone cream as a treatment for low testosterone levels (hypogonadism), which can help improve symptoms like low sex drive and erectile dysfunction 97

Application and Dosage

• The application of testosterone cream should be done once daily, preferably in the morning, with a dose of 20.25-40.5 mg per application, as recommended by the treatment guidelines 98

Safety Precautions

• The American Urological Association warns that children and women should never touch areas where testosterone cream has been applied, as accidental exposure can cause serious problems, including early puberty and enlarged genitals in children, and unwanted facial or body hair growth in women 99
• The American Heart Association recommends that patients with heart disease or those who have had a heart attack or stroke should wait 3-6 months after the event before starting testosterone therapy 97, 99, 100

Benefits and Expectations

• The Endocrine Society reports that testosterone therapy can provide improvements in sexual function, including increased sex drive and libido, and better erectile function, with benefits typically seen within 3-6 months 101
• The American College of Physicians notes that testosterone therapy provides little to no benefit for physical strength or athletic performance, memory or thinking ability, general fatigue or tiredness, or depression 101

Monitoring and Side Effects

• The American Urological Association recommends regular blood tests to check testosterone levels, blood count, and liver function, with a target testosterone level of 450-600 ng/dL (mid-normal range) 97, 102, 100
• The National Institutes of Health reports that common side effects of testosterone cream include skin reactions, acne, increased red blood cell count, and fluid retention, while serious side effects include chest pain, shortness of breath, and dizziness 103, 102, 100

Contraindications and Special Precautions

• The American Urological Association advises that testosterone cream should not be used in patients with prostate cancer, breast cancer, or those trying to father a child, and special precautions should be taken for patients with heart disease or those who have had a heart attack or stroke 97, 99, 100

Tapering Off Testosterone Injections

Understanding Discontinuation Approaches

• The American Urological Association guidelines recommend abrupt cessation of testosterone therapy, as there is no clinical benefit to gradual dose reduction, and this approach is the standard practice 104
• The European Association of Urology recommends gonadotropin therapy (hCG plus FSH) as first-line treatment for men with secondary hypogonadism who need fertility restoration, which directly stimulates the testes rather than waiting for natural pituitary recovery 104

Monitoring and Diagnostic Testing

• Measure morning total testosterone (between 8-10 AM) to assess recovery, as recommended by the guidelines, to evaluate the return of natural testosterone production 105
• Check LH and FSH levels to confirm the hypothalamic-pituitary axis is reactivating, which is essential for natural testosterone production recovery 104

Fertility Restoration

• Gonadotropin therapy (hCG plus FSH) is the evidence-based approach to restore both testosterone production and sperm counts, and is recommended for men who desire fertility restoration 104

Management of Hypogonadotropic Hypogonadism with Testosterone Therapy

Introduction to Testosterone Therapy

• The American Urological Association recommends targeting testosterone levels between 450-600 ng/dL (mid-normal range) for patients on testosterone therapy 106
• Testosterone replacement therapy should be individualized, with consideration of the patient's overall health, symptoms, and potential risks 106
• Patients should be monitored for hemoglobin and hematocrit levels, as testosterone therapy can increase the risk of erythrocytosis 106
• The Endocrine Society suggests that patients with hypogonadotropic hypogonadism who do not desire fertility should be treated with testosterone therapy, with regular monitoring of testosterone levels, hemoglobin, and hematocrit 106

Monitoring and Optimizing Testosterone Therapy

• The American Urological Association recommends measuring testosterone levels in the morning (8-10 AM) for patients on testosterone therapy 106
• For injectable testosterone, levels should be measured midway between injections (days 5-7 after injection) 106
• For transdermal testosterone, levels can be measured at any time after 2-3 months of stable therapy 106
• Patients should be monitored for cardiovascular symptoms, such as chest pain, shortness of breath, and dizziness, as testosterone therapy may increase the risk of cardiovascular events 106

Lifestyle Modifications

• The American Heart Association recommends that patients with hypogonadism, especially those with obesity, should aim to lose weight through calorie-restricted diets, which can improve testosterone levels without medication 106
• Regular physical activity should be encouraged, as it can also improve testosterone levels and overall health 106
• These lifestyle modifications should be implemented in conjunction with testosterone therapy 106

Contraindications to Testosterone Therapy

• The American Urological Association states that active desire to preserve fertility is an absolute contraindication to testosterone therapy, as it can cause prolonged and potentially irreversible azoospermia 106
• Other absolute contraindications include active or treated male breast cancer, hematocrit >54%, and severe untreated obstructive sleep apnea 106

Management of Elevated Hemoglobin and Hematocrit on Testosterone Therapy

Understanding Testosterone-Induced Erythrocytosis

• The American Urological Association recommends monitoring hematocrit levels and withholding testosterone therapy if hematocrit exceeds 54%, with consideration for dose reduction or therapeutic phlebotomy in select cases 107, 108, 109
• Testosterone stimulates erythropoiesis, leading to increased hemoglobin levels, with a reported increase of 15-20% during male puberty as testosterone rises 108, 109

Monitoring Algorithm

• The American College of Physicians recommends documenting baseline hematocrit or hemoglobin before initiating therapy, and hematocrit >54% is an absolute contraindication to starting testosterone 107, 108, 109
• Baseline assessment should include hematocrit or hemoglobin measurement, with follow-up monitoring at 2-3 months after treatment initiation and annually once stable 108, 109

Management Based on Hematocrit Level

• For hematocrit 50-52%, continue current therapy with closer monitoring, and consider dose reduction if trending upward 108, 109
• For hematocrit 52-54%, reduce testosterone dose by 25-50%, and consider switching from injectable to transdermal formulation 108, 109
• For hematocrit >54%, withhold testosterone therapy immediately, and consider therapeutic phlebotomy in high-risk patients 107, 108, 109

Special Considerations for High-Risk Patients

• Elderly patients and those with cardiovascular disease face greater risk due to elevated blood viscosity, which can aggravate coronary, cerebrovascular, or peripheral vascular disease 108, 109
• Target mid-normal testosterone levels (450-600 ng/dL) rather than upper-normal, and use transdermal formulations preferentially over injectables in high-risk patients 107, 108, 109

Formulation Switching Strategy

• If erythrocytosis develops on injectable testosterone, switch to transdermal gel or patch, which provides more stable day-to-day levels 108, 109

Therapeutic Phlebotomy: Use With Caution

• Reserve phlebotomy for hematocrit persistently >54% despite dose reduction, high-risk patients with hematocrit 52-54%, or symptomatic hyperviscosity 108, 109
• Phlebotomy protocol when indicated: remove 500 mL blood every 1-2 weeks until hematocrit <52%, and monitor iron studies to avoid iron deficiency 108

Critical Pitfalls to Avoid

• Do not ignore mild erythrocytosis (hematocrit 50-52%) in elderly patients or those with cardiovascular disease, as even modest elevations increase blood viscosity and thrombotic risk 108, 109
• Do not continue full-dose testosterone when hematocrit exceeds 54%, as this is an absolute indication to withhold therapy 107, 108, 109

Reassessing the Need for Testosterone Therapy

• If hematocrit remains persistently elevated (>52%) despite dose reduction and formulation change, reevaluate whether the patient is experiencing meaningful clinical benefit from testosterone, considering the small improvements in sexual function and minimal to no benefit for energy, physical function, or mood 107, 110, 111, 112

Testosterone Replacement Therapy in Elderly Males with Hypogonadism

Bone Mineral Density Improvement

• The American Urological Association notes that modest improvements in bone mineral density can be achieved with testosterone replacement therapy, with a 3.2% increase at the lumbar spine and a 1.4% increase at the femoral neck 113

Cardiovascular Risk Considerations

• The Mayo Clinic recommends avoiding testosterone replacement therapy in men with recent myocardial infarction or stroke within the past 3-6 months or severe/decompensated heart failure, and targeting mid-range testosterone levels (350-600 ng/dL) in elderly patients with cardiovascular risk factors 113

Special Considerations for Elderly Men

• The Endocrine Society suggests that weight loss of 5-10% can significantly increase endogenous testosterone production in obese elderly men with secondary hypogonadism, and that lifestyle modifications should be attempted before initiating testosterone replacement therapy 113
• The American Geriatrics Society notes that testosterone replacement therapy has minimal to no benefit for improving physical function, muscle strength, or frailty in elderly men, and that the primary indication remains sexual dysfunction 113

Management of Obesity-Associated Secondary Hypogonadism

Diagnostic Confirmation and Treatment

• Weight loss through low-calorie diets and regular physical activity is the first-line treatment for obesity-associated secondary hypogonadism, as this approach can reverse the condition by improving testosterone levels and normalizing gonadotropins, according to the European Association of Urology 114
• Repeat morning total testosterone (8-10 AM) on at least one additional occasion to confirm persistent levels <300 ng/dL, as recommended by the European Association of Urology 114
• Measure serum LH and FSH to distinguish primary (testicular) from secondary (hypothalamic-pituitary) hypogonadism, as suggested by the European Association of Urology 114
• Implement a hypocaloric diet with caloric restriction of 500-750 kcal/day below maintenance requirements, as recommended by the European Association of Urology 114
• Prescribe structured physical activity: minimum 150 minutes/week of moderate-intensity aerobic exercise plus resistance training 2-3 times weekly, according to the European Association of Urology 114
• Testosterone therapy can be considered in appropriately selected symptomatic patients, but only after confirming the patient does not desire fertility, as recommended by the European Association of Urology 114
• Testosterone therapy is absolutely contraindicated in men actively seeking fertility, as it suppresses spermatogenesis and causes prolonged, potentially irreversible azoospermia, according to the European Association of Urology 114
• Transdermal testosterone gel 1.62% at 40.5 mg daily is the preferred first-line formulation due to more stable day-to-day testosterone levels and lower risk of erythrocytosis compared to injectable preparations, as recommended by the European Association of Urology 114
• Monitor hematocrit at each visit—withhold treatment if >54% and consider phlebotomy in high-risk cases, as suggested by the European Association of Urology 114
• Never start testosterone without first attempting lifestyle modification in obesity-associated hypogonadism, as the condition is potentially reversible, according to the European Association of Urology 114
• Never initiate testosterone without confirming the patient does not desire fertility, as this causes irreversible suppression of spermatogenesis, as recommended by the European Association of Urology 114
• Never use testosterone therapy for weight loss, energy improvement, or athletic performance in men with obesity-related hypogonadism—these are not evidence-based indications, according to the European Association of Urology 114
• Never diagnose hypogonadism based on symptoms alone or single testosterone measurement—always confirm with repeat morning testing and measure gonadotropins, as recommended by the European Association of Urology 114

HCG Monotherapy for Testosterone and Fertility Restoration Post-TRT

Introduction to HCG Monotherapy

• The American Urological Association (AUA) and the American Society for Reproductive Medicine (ASRM) recommend HCG monotherapy as a guideline-recommended approach for men with secondary hypogonadism who desire fertility preservation 115

Evidence for HCG Monotherapy Effectiveness

• HCG alone can restore testosterone but may require addition of FSH for optimal sperm production 115
• The AUA/ASRM guidelines explicitly state that HCG (with or without FSH) should be used for infertile men with hypogonadotropic hypogonadism 115

Recommended HCG Protocol

• If fertility is the primary goal, add recombinant FSH 75-150 units subcutaneously 2-3 times per week after 3-6 months if sperm counts remain low 115

Critical Considerations for HCG Therapy

• Never restart testosterone if fertility is desired, as this will immediately suppress spermatogenesis again 115
• Combined HCG + FSH therapy produces better fertility outcomes than HCG alone in men with secondary hypogonadism 115
• Guidelines still recommend HCG (with or without FSH) as first-line for fertility restoration in secondary hypogonadism 115

Diagnostic Criteria and Workup for Male Hypogonadism

Essential Laboratory Assessments

• Measurement of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH) is mandatory to differentiate primary (testicular) from secondary (hypothalamic‑pituitary) hypogonadism. 116
• Primary hypogonadism is characterized by elevated LH/FSH with low testosterone, whereas secondary hypogonadism shows low or low‑normal LH/FSH with low testosterone. 116

Testosterone Thresholds and Confirmation

• The 2025 European Association of Urology guideline defines biochemical hypogonadism as two separate morning total testosterone measurements (8–10 AM) < 300 ng/dL. 116
• A single total testosterone value of 370 ng/dL is above the diagnostic threshold and therefore does not confirm hypogonadism. 116
• Repeat morning testing is required because of diurnal variation and assay variability. 116

Interpretation of Free Testosterone and SHBG

• Free testosterone should be measured by equilibrium dialysis (gold standard) or calculated using validated formulas (e.g., Vermeulen) rather than direct immunoassays, which are unreliable. 116
• With a low SHBG (≈10 nmol/L), the expected free testosterone is elevated, so a reported low free testosterone suggests a laboratory error. 116

Role of DHEA‑S

• DHEA‑S is produced by the adrenal glands and does not aid in diagnosing hypogonadism nor distinguish primary from secondary forms; it should not be included in the diagnostic work‑up. 116

Clinical Decision‑Making and Treatment Indications

• Diagnosis of hypogonadism requires both confirmed low testosterone (per the ≥2 morning measurements rule) and the presence of specific symptoms. 116
• Symptoms that justify treatment are diminished libido and erectile dysfunction; other nonspecific complaints (fatigue, low energy, mood changes) lack proven benefit from testosterone therapy. 116
• Testosterone therapy is contraindicated in men who desire fertility preservation; in secondary hypogonadism, gonadotropin therapy may restore both fertility and normal testosterone levels. 116

Common Pitfalls to Avoid

• Do not diagnose hypogonadism on a single testosterone measurement; two morning values are required. 116
• Do not rely on symptoms alone without biochemical confirmation; symptoms are nonspecific and overlap with many conditions. 116
• Never omit LH/FSH testing once low testosterone is confirmed, because the distinction between primary and secondary hypogonadism directs therapy and fertility counseling. 116
• Avoid direct immunoassay measurements of free testosterone; use equilibrium dialysis or calculated values to ensure accuracy. 116

Suggested Diagnostic Algorithm (summary)

Preferred Testosterone Formulation to Reduce Erythrocytosis Risk

Formulation Choice

• Transdermal testosterone gel is strongly preferred over injectable testosterone for transgender men with elevated hematocrit because injectable preparations are associated with a markedly higher incidence of erythrocytosis (approximately 43.8 % of users) compared with transdermal gels (approximately 15.4 % of users). A typical initiation regimen is a 1.62 % gel applied once daily. This recommendation is based on the evidence presented by the cited source and reflects moderate‑quality observational data. 117

Risk of Elevated Hemoglobin and Hematocrit with Testosterone Replacement Therapy

Incidence by Formulation

118

Temporal Pattern of Hematocrit Rise

Comparative Risk and Formulation Preference

Thromboembolic Safety Evidence

Testosterone Therapy–Induced Erythrocytosis

Incidence by Formulation and Dose

• Injectable testosterone carries the highest risk, with ≈44 % of users developing hematocrit > 52 % during treatment. 119
• Transdermal testosterone patches show an intermediate risk, with ≈15 % of users developing elevated hematocrit. 119
• Testosterone gel produces a dose‑dependent risk:
  
  • Low dose (≈5 mg/day) → ≈3 % develop erythrocytosis
  • Moderate dose (≈50 mg/day) → ≈11 % develop erythrocytosis
  • High dose (≈100 mg/day) → ≈18 % develop erythrocytosis. 119

Temporal Pattern of Hematologic Change

• The most pronounced rise in hemoglobin and hematocrit occurs within the first 3 months of initiating testosterone therapy, with values increasing from subnormal to mid‑normal ranges. 119

Clinical Consequences

• Elevated blood viscosity from testosterone‑induced erythrocytosis can exacerbate vascular disease in coronary, cerebrovascular, and peripheral circulations, particularly in older adults or those with pre‑existing cardiovascular disease. 119
• Despite the theoretical thrombotic risk, large prospective studies have not demonstrated a definitive increase in thromboembolic events attributable to testosterone therapy. 119

Letrozole Use in Men with Low Testosterone and Elevated Estradiol

Mechanism of Action

• Aromatase inhibition by letrozole blocks the conversion of testosterone to estradiol, reducing estradiol‑mediated negative feedback on the hypothalamus‑pituitary axis; this restores GnRH pulsatility, increases LH and FSH secretion, and stimulates endogenous testosterone production while lowering circulating estradiol. (European Association of Urology) 120, 121

Indications & Candidate Selection

Hormonal Criteria

• Men should have confirmed low morning total testosterone < 300 ng/dL on two separate measurements to establish hypogonadism. (American Urological Association) 122
• Low or low‑normal LH and FSH together with low testosterone indicate secondary (hypogonadotropic) hypogonadism and identify patients who can respond to reduced estradiol feedback. (American Urological Association) 122
• Elevated estradiol > 40–50 pg/mL (≈ 40 pmol/L) supports the use of an aromatase inhibitor. (American Urological Association) 122
• Free testosterone assessment is recommended, especially in obese men where SHBG may be altered. (American Urological Association) 122

Clinical Scenarios

• Letrozole is an appropriate off‑label option for men with low testosterone and elevated estradiol who wish to avoid testosterone replacement therapy, particularly when fertility preservation is desired or when obesity‑related aromatization drives the hormonal imbalance. (European Association of Urology) 120, 121
• Men desiring fertility preservation benefit from letrozole because it stimulates endogenous testosterone without suppressing spermatogenesis, unlike testosterone therapy which causes azoospermia. (European Association of Urology) 120, 121

Clinical Efficacy

Hormonal Improvements

• Moderate‑quality evidence shows that letrozole leads to rapid hormonal normalization, with total testosterone reaching mid‑normal levels (≈ 500–600 ng/dL) within 6 weeks in obese secondary hypogonadal men. (European Association of Urology) 120, 121

Sexual Function Outcomes

• Small but statistically significant improvements in sexual function and libido have been observed (standardized mean difference ≈ 0.35), comparable to the effect size of testosterone replacement. (American Urological Association) 122

Fertility‑Related Benefits

• Letrozole preserves or improves spermatogenesis, making it the preferred option for men seeking fertility, whereas testosterone replacement is contraindicated because it suppresses spermatogenesis and can cause prolonged azoospermia. (American Urological Association) 122

Advantages Over Testosterone Replacement

• Preserves fertility by maintaining or enhancing sperm production, whereas testosterone therapy induces azoospermia. (European Association of Urology) 120, 121

Limitations & Contraindications

• Letrozole is ineffective in primary hypogonadism (elevated LH/FSH) because the testes cannot respond to increased gonadotropin stimulation. (American Urological Association) 122
• The drug is not FDA‑approved for male hypogonadism; its use is off‑label. (American Urological Association) 122
• Evidence quality is moderate; most studies are small, uncontrolled, and prospective randomized trials are lacking. (European Association of Urology) 120, 121

Monitoring & Follow‑Up

• 6‑week assessment: repeat total and free testosterone, estradiol, LH, and FSH to confirm target mid‑normal testosterone and avoid excessive estradiol suppression. (American Urological Association) 122
• 3–4‑month assessment: repeat hormonal panel and perform semen analysis if fertility is a goal; evaluate libido and erectile function. (American Urological Association) 122
• Ongoing surveillance: every 6–12 months once stable, monitor testosterone, estradiol, hematocrit, and symptom burden. (American Urological Association) 122

Decision Points & Switching to Testosterone Replacement

• At 12 months: if sexual function has not improved despite achieving target testosterone levels, discontinue letrozole or transition to testosterone replacement (provided fertility is no longer a priority). (American Urological Association) 122
• When fertility is achieved or no longer desired: consider switching to testosterone replacement for potentially greater symptomatic benefit. (American Urological Association) 122
• Primary hypogonadism (elevated LH/FSH) or severe hypogonadism (testosterone < 150 ng/dL) requiring rapid normalization are indications to use testosterone replacement instead of letrozole. (American Urological Association) 122

All facts are derived from cited sources; strength of evidence is indicated where reported.

Evidence‑Based Recommendations for Testosterone Testing in Adult Men

Diagnostic Timing

• Morning testosterone measurements should be obtained between 8:00 AM and 10:00 AM because diurnal variation causes lower values later in the day, risking false‑positive diagnoses. 123

Additional Testing for Borderline or Obese Patients

• In men whose total testosterone is near the lower limit of normal (≈ 230–350 ng/dL) or who are obese, free testosterone should be measured by equilibrium dialysis together with sex‑hormone‑binding globulin (SHBG) to accurately assess androgen status. 123
• In obese men, low total testosterone may reflect reduced SHBG with normal free testosterone, indicating that true hypogonadism is absent. 123
• A proportion of obese men exhibit genuinely low free testosterone due to increased aromatization of testosterone to estradiol in adipose tissue. 123

Special Populations

• Men with type 2 diabetes should have testosterone measured even in the absence of hypogonadal symptoms. 123

Guidelines for Monitoring and Dose Adjustment of Intramuscular Testosterone Therapy

Pharmacokinetic Considerations

• Peak serum testosterone concentrations occur 2–5 days after an intramuscular injection, often transiently exceeding the upper limit of normal with standard dosing. 124
• Serum testosterone concentrations typically return to baseline by days 10–14 after the injection. 124

Monitoring Schedule

• The first follow‑up visit should be scheduled 1–2 months after therapy initiation to evaluate clinical response and consider dose escalation if symptoms persist with suboptimal levels. 124
• During the first year, testosterone levels and related assessments should be repeated every 3–6 months. 124
• After achieving stable levels, monitoring can be reduced to once yearly. 124

Dose‑Adjustment Algorithm

• When the patient reports an adequate clinical response, no dose change is required even if testosterone levels are in the low‑normal range. 124
• If the clinical response is suboptimal and testosterone levels are low‑normal or below, the dose should be increased. 124
• When maximal recommended transdermal doses fail to achieve adequate testosterone concentrations, conversion to intramuscular injection therapy should be considered. 124

Safety and Ancillary Monitoring

• Hematocrit should be measured at each visit; treatment should be withheld if hematocrit exceeds 54 % and phlebotomy considered for high‑risk individuals. 124
• Prostate‑specific antigen (PSA) should be checked in men ≥ 40 years; refer for urologic evaluation if PSA rises > 1.0 ng/mL within the first 6 months or > 0.4 ng/mL per year thereafter. 124
• A digital rectal examination should be performed at each visit to screen for prostate abnormalities. 124
• Assessment of symptomatic response—particularly sexual function and libido—should be documented at every encounter. 124

Expected Clinical Outcomes

• Testosterone therapy yields a modest improvement in sexual function (standardized mean difference ≈ 0.35) but shows little to no impact on physical functioning, energy, vitality, depressive symptoms, or cognition. 124
• If the patient experiences satisfactory improvement in sexual symptoms, dose adjustment is unnecessary even when testosterone levels remain in the low‑normal range. 124

Testosterone Evaluation Guidelines for Adult Men

Reference Ranges

• The American Urological Association (AUA) notes that, for a healthy adult male, total serum testosterone normally ranges from approximately 264 ng/dL to 916 ng/dL, with a mean value around 500–600 ng/dL. 125

Diagnostic Thresholds

• The AUA defines total testosterone < 300 ng/dL as the diagnostic threshold for low testosterone in all adult age groups, and requires confirmation with two separate early‑morning measurements (8–10 AM). 125
• Values between 231 ng/dL and 346 ng/dL are considered a “gray zone”; in symptomatic men a 4–6‑month therapeutic trial may be considered after a risk‑benefit discussion. 125
• Levels > 350 ng/dL generally do not warrant testosterone replacement therapy, regardless of symptoms. 125

Measurement Recommendations

• Morning timing is mandatory because testosterone peaks between 8 AM and 10 AM; measurements taken later risk false‑positive hypogonadism diagnoses. 125
• Two separate measurements are required due to significant intra‑individual variability and assay differences; a single measurement is insufficient for diagnosis. 125

Laboratory Variability

• Reference‑range limits reported by laboratories vary widely, with lower limits ranging from 130 ng/dL to 450 ng/dL and upper limits from 486 ng/dL to 1,593 ng/dL. This variability directly influences clinical decision‑making. 125
• Consequently, up to 25 % of men receiving testosterone therapy do not actually meet diagnostic criteria for hypogonadism. 125

Clinical Algorithm for Testosterone Assessment

Common Pitfalls to Avoid

• Do not diagnose hypogonadism on a single measurement.
• Do not test outside of morning hours (8–10 AM).
• Do not ignore free testosterone assessment in borderline or obese patients. 125

Guideline for Evaluating Functional Hypogonadism in Men with Elevated SHBG

Diagnostic Methods

• Equilibrium dialysis combined with LC‑MS/MS is the only FDA‑cleared method for accurately measuring free testosterone; it is not routinely offered by commercial laboratories. 126
• The free androgen index (FAI) can be calculated as (total testosterone ÷ SHBG) × 100 to estimate bioavailable testosterone when equilibrium dialysis is unavailable. 126
• Using the FAI calculation circumvents the known inaccuracy of direct immunoassays for free testosterone in the setting of abnormal SHBG. 126

Interpretation of Results

• An FAI < 30 indicates true hypogonadism even when total testosterone is in the borderline‑normal range. 126, 127
• In men with markedly elevated SHBG, the presence of diminished libido markedly raises the pre‑test probability of biochemical hypogonadism. 126
• Interpretation algorithm:
  
  • If total testosterone is 231–346 ng/dL (gray zone) and FAI < 30, functional hypogonadism due to elevated SHBG is likely. 126
  • If total testosterone > 350 ng/dL but FAI < 30 together with low libido, SHBG‑mediated functional hypogonadism may be present and could justify treatment. 126

Etiology of Elevated SHBG

• Liver disease (e.g., cirrhosis) is a recognized cause of markedly increased SHBG levels. 127
• Hyperthyroidism also elevates SHBG production. 127

Clinical Management Steps

• Diagnostic algorithm: obtain two separate morning total testosterone measurements, calculate FAI, request free testosterone by equilibrium dialysis when possible, and measure LH and FSH to differentiate primary from secondary hypogonadism. 126
• Recommended clinical approach: repeat morning total testosterone on two occasions, compute FAI, and assess LH/FSH to confirm diagnosis and guide therapy decisions. 126

Indications for Initiating Clomiphene in Men with Confirmed Hypogonadism

Criteria Defining Appropriate Candidates

• Clomiphene is indicated when both morning total testosterone measurements are below 300 ng/dL and luteinizing hormone (LH) and follicle‑stimulating hormone (FSH) levels are low or low‑normal, confirming secondary (hypogonadotropic) hypogonadism. This hormonal profile predicts a favorable response to estrogen‑receptor blockade, which restores hypothalamic‑pituitary signaling and endogenous testosterone production. 128

Fertility‑Preserving Indication

• Clomiphene should be considered for men who desire to preserve fertility, because it stimulates endogenous testosterone without suppressing spermatogenesis, unlike exogenous testosterone replacement. The drug’s mechanism allows maintenance of normal sperm production while correcting low testosterone levels. 128

Diagnosis and Management of Testosterone Deficiency and Erectile Dysfunction

Initial Diagnostic Criteria

• A diagnosis of testosterone deficiency requires a morning total testosterone < 300 ng/dL on two separate measurements (8–10 AM) together with specific symptoms such as reduced libido or erectile dysfunction. [129][130]

Laboratory Evaluation

Core Hormone Tests

• Total testosterone should be measured fasting between 8–10 AM using a highly accurate assay (LC‑MS/MS certified by the CDC Hormone Standardization Program). This assay is recommended by the American Urological Association (AUA). 129
• Repeat total testosterone on a second occasion because of significant intra‑individual variability; this repeat testing is also endorsed by the AUA. [129][130]
• LH and FSH must be obtained after confirming low testosterone to differentiate primary (elevated LH/FSH) from secondary (low/normal LH/FSH) hypogonadism; the distinction guides therapy and fertility counseling (AUA). [129][130]
• If LH < 1.5 UI/L and FSH < 1.5 UI/L together with total testosterone < 150 ng/dL, a pituitary MRI should be ordered immediately, even in the absence of hyperprolactinemia (AUA). 130
• Prolactin should be measured in all men with low testosterone and low/normal LH‑FSH; if prolactin exceeds 1.5 × the upper limit of normal, a pituitary MRI is indicated to exclude prolactinoma (AUA and Endocrine Society). [130][131]

Additional Baseline Tests

• PSA must be obtained in all men > 40 years before initiating testosterone therapy; a PSA > 4.0 ng/mL mandates urologic evaluation and a documented negative prostate biopsy prior to treatment (AUA/Endocrine Society). [130][131]
• In high‑risk groups (e.g., African‑American men or those with a first‑degree relative with prostate cancer), a PSA > 3.0 ng/mL also triggers further urologic work‑up (AUA). 130
• Estradiol (ultrasensitive) is measured only when patients present with breast tenderness, gynecomastia, or related symptoms before starting therapy (AUA). 130
• Baseline hematocrit/hemoglobin are recorded to monitor for potential erythrocytosis during therapy (Endocrine Society). 131
• Fasting glucose and HbA1c are obtained to rule out diabetes before therapy (AUA). 130
• Full lipid profile is recommended as part of the baseline metabolic assessment (Endocrine Society). 131
• TSH should be measured to exclude thyroid dysfunction that can mimic hypogonadal symptoms (AUA). 130

Tests Not Routinely Required

• Vitamin D and CRP are not part of the standard diagnostic work‑up for hypogonadism according to AUA and Endocrine Society guidelines. [129][130]

Imaging Recommendations

• Pituitary MRI is indicated when any of the following are present:

• Scrotal ultrasound is not a routine component of hypogonadism evaluation; it is reserved for cases with abnormal testicular examination findings such as nodules or masses (AUA). [129][130]

Initiation of Testosterone Therapy

• Therapy should not be started without completing the pituitary evaluation in cases of secondary hypogonadism, to avoid missing treatable lesions (AUA). (implicit from imaging criteria)

• Prior to initiation, confirm that the patient does not desire future fertility, as testosterone therapy can cause prolonged azoospermia (AUA). 130

Monitoring Protocol

Early Follow‑up (First 12 Months)

• First follow‑up visit (1–2 months): assess clinical response, adjust dose if symptoms persist with sub‑optimal hormone levels; obtain total and free testosterone and repeat hematocrit/hemoglobin (Endocrine Society). 131

• Subsequent visits every 3–6 months during year 1:

Long‑term Monitoring (After First Year)

• Annual visits (once stable): repeat PSA (men > 40), lipid profile, and digital rectal examination (Endocrine Society). 131

Criteria for Urologic Referral

• PSA rise > 1.0 ng/mL within the first 6 months of therapy.
• PSA increase > 0.4 ng/mL per year after the initial 6 months.
• Development of a palpable prostate nodule, induration, or asymmetry on digital rectal exam (Endocrine Society). 131

Common Pitfalls to Avoid

• Do not diagnose testosterone deficiency on a single measurement; require two separate morning values (AUA). [129][130]
• Do not measure testosterone outside the 8–10 AM window, as this increases false‑positive rates (AUA). 129
• Do not omit LH/FSH testing after confirming low testosterone; the results direct treatment choice and fertility counseling (AUA). 130
• Do not rely solely on symptoms without biochemical confirmation (AUA). [129][130]
• Approximately 50 % of men receiving testosterone therapy never have their hormone levels re‑checked, representing a significant safety gap (AUA). 129
• Up to 25–30 % of treated men do not meet formal diagnostic criteria for testosterone deficiency, highlighting the need for strict adherence to testing protocols (AUA). 129
• Do not start testosterone in patients who wish to preserve fertility without thorough counseling, as therapy can cause prolonged azoospermia (AUA). 130

Workup for Secondary Hypogonadism

Diagnostic Confirmation

• In adult men suspected of secondary hypogonadism, obtain two separate fasting morning total testosterone measurements (8–10 AM) each <300 ng/dL, then measure serum LH and FSH to confirm low or inappropriately normal gonadotropins and proceed with systematic evaluation for reversible causes and pituitary pathology. 132
• Both morning testosterone values must be <300 ng/dL to establish biochemical hypogonadism. 132

Gonadotropin Assessment

• Secondary hypogonadism is defined by low or inappropriately normal LH and FSH levels together with low testosterone, whereas primary hypogonadism shows elevated gonadotropins. 132

Pituitary Imaging Indications

• Order pituitary MRI when visual field defects (e.g., bitemporal hemianopsia) or anosmia are present, as these findings suggest a sellar mass. 132

Evaluation for Reversible Causes

• Screen for chronic systemic diseases—including type 2 diabetes, HIV infection, chronic organ failure, and inflammatory conditions—as they can transiently suppress the hypothalamic‑pituitary axis and contribute to secondary hypogonadism. 132
• Perform iron studies when hemochromatosis is suspected, because iron overload is a recognized cause of secondary hypogonadism. 132

Evidence‑Based Guidance on Testosterone Therapy for Men

Sexual Symptoms with Proven Testosterone Responsiveness

• Decreased spontaneous or morning erections are among the few symptoms that reliably improve with testosterone replacement, as demonstrated in a 2018 study published in The Journal of Urology【133】.
  Strength of evidence: strong (randomized controlled trial).

Non‑Sexual Symptoms Not Correlated with Testosterone Levels

• Fatigue, low energy, depressed mood, poor concentration, and reduced physical strength show little or no correlation with serum testosterone concentrations and exhibit minimal to no improvement after testosterone therapy, according to a 2020 systematic review in Annals of Internal Medicine【134】.
  Strength of evidence: moderate (large cohort and meta‑analysis).
• In a large preventive‑medicine cohort, fatigue, depression, and erectile dysfunction were not statistically associated with low testosterone levels (p > 0.6)【134】.
  Strength of evidence: moderate (observational data).

Expected Clinical Benefits and Limitations of Testosterone Replacement

• When both biochemical criteria (morning total testosterone < 300 ng/dL) and qualifying sexual symptoms (e.g., diminished libido or erectile dysfunction) are met, testosterone therapy yields a small but statistically significant improvement in sexual function (standardized mean difference ≈ 0.35)【134】.
  Strength of evidence: moderate (meta‑analysis of randomized trials).
• The same evidence base indicates little to no benefit for energy levels, physical function, mood, or cognition with testosterone treatment【134】.
  Strength of evidence: moderate (meta‑analysis).
• Consequently, testosterone therapy is not recommended for men whose primary complaints are fatigue, low energy, or mood disturbances in the absence of sexual symptoms, even if low testosterone is confirmed biochemically【134】.
  Strength of evidence: moderate (clinical guideline synthesis).

Guideline for Evaluation and Management of Elevated SHBG with Low Free Testosterone in Men

Etiology of Elevated SHBG

• Aging, hyperthyroidism, hepatic disease, HIV/AIDS, smoking, and certain medications (e.g., anticonvulsants, estrogens, thyroid hormone) are the most common causes of elevated SHBG in men not receiving exogenous testosterone. 135

Diagnostic Evaluation

Confirmation of Biochemical Hypogonadism

• Obtain two separate fasting morning total testosterone measurements (8–10 AM); biochemical hypogonadism is defined when both values are < 300 ng/dL. Single measurements are insufficient because of diurnal variation and assay variability. 135

Assessment of Free Testosterone

• In the “gray zone” (total testosterone ≈ 231–346 ng/dL), measure free testosterone by equilibrium dialysis (gold standard) or calculate the free androgen index (FAI = total testosterone ÷ SHBG × 100). An FAI < 30 indicates true hypogonadism even when total testosterone is borderline‑normal. 135

Differentiation of Primary vs. Secondary Hypogonadism

• After confirming low testosterone, measure serum LH and FSH:
• This distinction is critical because secondary hypogonadism can be treated with gonadotropin therapy to restore both testosterone production and fertility, whereas primary hypogonadism requires testosterone replacement, which permanently suppresses fertility. 135

Identification of Reversible Causes of Elevated SHBG

• Screen for and address the following before considering testosterone therapy:

Evaluation of Reversible Causes of Secondary Hypogonadism

• Exclude secondary contributors such as:

Management Strategy

First‑Line: Treat Underlying Reversible Conditions

• Obesity‑related secondary hypogonadism – implement a hypocaloric diet (≈ 500–750 kcal/day deficit) and structured exercise (≥ 150 min/week moderate‑intensity aerobic activity plus resistance training 2–3 times/week); a 5–10 % weight loss can markedly increase endogenous testosterone.
• Hyperthyroidism – treat with antithyroid drugs, radioiodine, or surgery.
• Hepatic disease – optimize liver function; in cirrhosis, use the free testosterone index (total testosterone ÷ SHBG < 0.3) to define hypogonadism.
• Medication adjustment – discontinue or substitute SHBG‑elevating drugs when feasible. 135

Pharmacologic Therapy

For Men Desiring Fertility Preservation

• Gonadotropin therapy (recombinant hCG + FSH) is mandatory in secondary hypogonadism with fertility concerns; exogenous testosterone is contraindicated because it causes prolonged azoospermia. Combined hCG + FSH restores both serum testosterone and spermatogenesis. 135

For Men Not Seeking Fertility

• Testosterone replacement is indicated only after confirming biochemical hypogonadism (two morning testosterone < 300 ng/dL) and the presence of specific symptoms (diminished libido or erectile dysfunction).

Expected Treatment Outcomes

• Testosterone therapy yields a small but statistically significant improvement in sexual function and libido (standardized mean difference ≈ 0.35).
• There is little to no effect on physical functioning, energy, vitality, depressive symptoms, or cognition.
• The primary therapeutic indication is sexual dysfunction (low libido, erectile dysfunction).
• Fatigue, low energy, mood disturbances, and cognitive complaints show minimal or no improvement even with confirmed hypogonadism.
• Modest favorable changes in metabolic parameters (insulin resistance, triglycerides, HDL cholesterol) may be observed. 135

Monitoring and Safety

Baseline Assessments

• Hematocrit/hemoglobin (absolute contraindication if > 54 %).
• Prostate‑specific antigen (PSA) for men > 40 years; PSA > 4.0 ng/mL requires urologic evaluation and a negative prostate biopsy before initiating therapy. 135

Follow‑Up Schedule

• 2–3 months after initiation – measure serum testosterone (mid‑interval for injectables), hematocrit, and PSA.
• Every 3–6 months during the first year – repeat testosterone, hematocrit, PSA, lipid profile, and perform digital rectal examination.
• Annually thereafter – continue the same panel if stable. 135

Safety Thresholds

• Withhold testosterone if hematocrit rises > 54 %; consider therapeutic phlebotomy in high‑risk individuals.
• Refer to urology if PSA increases > 1.0 ng/mL within the first 6 months or > 0.4 ng/mL per year thereafter.
• Discontinue therapy at 12 months if there is no documented improvement in sexual function. 135

Critical Pitfalls to Avoid

• Do not diagnose hypogonadism on a single testosterone measurement or on symptoms alone; require two fasting morning values < 300 ng/dL plus specific sexual symptoms.
• Always obtain LH and FSH after confirming low testosterone; the primary vs. secondary distinction guides therapy and fertility counseling.
• Never initiate testosterone without confirming the patient does not desire fertility, as exogenous testosterone can cause prolonged azoospermia.
• Avoid direct immunoassays for free testosterone in men with abnormal SHBG; use equilibrium dialysis or calculate the free androgen index.
• Do not prescribe testosterone for weight loss, general energy enhancement, or athletic performance, as these are not evidence‑based indications. 135

Target Testosterone Levels for Injectable Therapy

Recommended Serum Concentration

• Aim for mid‑normal serum testosterone concentrations of 500–600 ng/dL when the level is drawn at the midpoint between injections (e.g., days 5–7 for weekly dosing or days 7–10 for bi‑weekly dosing) in adult men receiving testosterone enanthate or cypionate injections. 136

Monitoring and Follow‑Up of Testosterone Therapy

Initial Follow‑Up (2–3 Months)

• After starting testosterone, measure total testosterone (timed midway between injections for injectable preparations), hematocrit, and PSA; evaluate clinical response—particularly improvement in sexual function and libido—and adjust the dose if symptoms persist with sub‑optimal hormone levels. 137

Ongoing Monitoring (Every 3–6 Months During the First Year, Then Annually)

• At each follow‑up visit repeat total testosterone, hematocrit, PSA, and perform a digital rectal examination to ensure safety and therapeutic adequacy. 137

PSA‑Based Referral to Urology

• Refer the patient to a urologist if PSA rises > 1.0 ng/mL within the first 6 months of therapy or increases > 0.4 ng/mL per year thereafter. 137

Cardiovascular Safety of Transdermal Testosterone Therapy

Major Adverse Cardiac Events

• Evidence: In the 2023 TRAVERSE randomized controlled trial (5,246 men, ages 45‑80 years, confirmed hypogonadism, with pre‑existing or high cardiovascular risk), transdermal testosterone gel showed no significant increase in major adverse cardiac events compared with placebo over a mean follow‑up of 21.7 months.
  Strength of evidence: Large‑scale RCT, moderate‑to‑high quality. 138

Stroke Risk

• Evidence: The same TRAVERSE trial found no significant difference in non‑fatal stroke incidence between men receiving transdermal testosterone gel and those receiving placebo, indicating that initiating or continuing therapy in this population does not raise stroke risk.
  Strength of evidence: Large‑scale RCT, moderate‑to‑high quality. 138

Guideline Recommendations for Laboratory Evaluation of Low Testosterone

Confirmation of Hypogonadism

• In adult men, diagnose hypogonadism only after two separate fasting morning (8–10 AM) total testosterone measurements < 300 ng/dL performed in the same laboratory to account for diurnal variation and assay variability. 139

Initial Hormone Assessment

• Measure serum LH and FSH in every man with confirmed low testosterone to differentiate primary (testicular) from secondary (hypothalamic‑pituitary) hypogonadism. 139
• When LH and/or FSH are low or inappropriately normal, obtain a serum prolactin level to screen for hyperprolactinemia that may indicate pituitary pathology. 139
• If an initial prolactin result is elevated, repeat the assay to verify that the elevation is not a laboratory artifact. 139
• Persistently elevated prolactin (> 1.5 × the assay’s upper limit of normal) mandates referral to endocrinology and pituitary magnetic resonance imaging (MRI) to evaluate for a prolactinoma. 139

Pituitary Imaging Criteria

• Order pituitary MRI in any man whose total testosterone is < 150 ng/dL and whose LH and FSH are < 1.5 IU/L, irrespective of prolactin level, because non‑functioning adenomas may be present. 139
• MRI is also indicated when prolactin exceeds 1.5 × ULN, when visual field defects (e.g., bitemporal hemianopsia) are detected, or when anosmia is reported, as these findings suggest a sellar mass. 139

Screening in High‑Risk Populations

• Measure testosterone (even in the absence of classic hypogonadal symptoms) in men with any of the following high‑risk conditions: unexplained anemia, decreased bone mineral density, diabetes mellitus, recent chemotherapy, testicular radiation exposure, HIV infection, chronic narcotic use, chronic corticosteroid therapy, or known pituitary disorders. 139

Key Diagnostic Pitfalls

• Do not rely on a single testosterone measurement; two appropriately timed morning values are required for a reliable diagnosis. 139
• Never omit LH/FSH testing after confirming low testosterone, because the primary vs. secondary distinction directs treatment choice and fertility counseling. 139
• Do not forgo pituitary imaging when testosterone is < 150 ng/dL with low gonadotropins, as this may miss treatable pituitary lesions. 139

Testosterone Therapy for Adult Men – Evidence‑Based Diagnostic and Therapeutic Recommendations

Diagnostic Requirements

• Confirm biochemical hypogonadism with two separate fasting morning total testosterone measurements (8–10 AM) both < 300 ng/dL before any therapy is considered. This dual‑test approach reduces misclassification due to diurnal variation and assay variability. [140][141]

• Do not diagnose hypogonadism on a single testosterone value or on symptoms alone; both laboratory confirmation and appropriate clinical features are mandatory. [140][141]

Symptom Assessment

• Therapy is justified only for men with diminished libido and/or erectile dysfunction as primary qualifying symptoms. These specific sexual symptoms correlate with measurable benefit from testosterone replacement. [140][141]

• Nonspecific symptoms such as fatigue, low energy, or mood changes should not trigger initiation of therapy, because response in these domains is minimal even when hypogonadism is biochemically confirmed. [140][142]

Treatment Benefits

• Testosterone replacement produces a small but statistically significant improvement in sexual function and libido (standardized mean difference ≈ 0.35). This benefit is consistent across multiple randomized trials. [140][142]143

• Overall quality‑of‑life gains are modest and confined mainly to sexual‑function domains, with no meaningful impact on broader health‑related quality of life measures. [140][142]143

Limitations of Efficacy

• There is little to no clinically relevant effect on energy, vitality, physical functioning, depressive symptoms, or cognition; effect sizes for these outcomes are negligible. [140][142]143

• Improvement in fatigue/energy is clinically insignificant (standardized mean difference ≈ 0.17), underscoring the limited utility of testosterone for non‑sexual symptoms. (Evidence from the same trials) [140][142]143

Evidence on Pharmacokinetics, Dosing Frequency, and Safety of Intramuscular Testosterone Therapy

Pharmacokinetic Profile of Intramuscular Injections

• In adult men with hypogonadism receiving intramuscular testosterone enanthate or cypionate, serum testosterone peaks 2–5 days after each injection and returns to baseline by days 10–14, creating a characteristic “roller‑coaster” pattern. 144

• The supraphysiologic peak that occurs 2–5 days post‑injection is linked to a heightened risk of adverse events, most notably erythrocytosis. 144

Impact of Injection Frequency on Hormone Stability

• Weekly intramuscular dosing (e.g., 50–100 mg every 7 days) reduces the magnitude of testosterone fluctuations compared with bi‑weekly (every 14 days) regimens, thereby minimizing the “roller‑coaster” effect. 144

• Bi‑weekly dosing (100–200 mg every 2 weeks) produces greater serum testosterone variability than weekly dosing, yet remains clinically effective for symptom management. 144

Safety Outcomes Associated with Intramuscular Formulations

• Erythrocytosis develops in approximately 43.8 % of patients treated with intramuscular testosterone injections, a markedly higher incidence than the 15.4 % observed with transdermal testosterone preparations. 144

Management of Erythrocytosis in Patients Receiving Testosterone Therapy

Risks Associated with Elevated Hematocrit

• Elevated hematocrit increases blood viscosity, which can exacerbate coronary, cerebrovascular, and peripheral arterial disease—particularly hazardous in older adults and those with pre‑existing cardiovascular disease. American College of Cardiology 145
• Even modest hematocrit elevations (50–52%) in elderly or cardiovascular‑high‑risk patients raise blood viscosity and thrombotic risk, therefore should not be ignored. American Heart Association 146

Indications for Therapeutic Phlebotomy

• Phlebotomy is recommended only when hematocrit remains > 54% despite dose reduction, in high‑risk patients whose hematocrit is 52–54%, or when symptomatic hyperviscosity is present. American Heart Association 146

Phlebotomy Protocol

The above regimen should be continued until the hematocrit falls below 52%, with iron parameters checked regularly to avoid iatrogenic iron deficiency. American Heart Association 146

Potential Harms of Phlebotomy

• Repeated phlebotomy lowers tissue oxygen partial pressure and depletes iron stores, which may paradoxically increase thrombotic risk. American Heart Association 146
• Iron deficiency in the setting of erythrocytosis reduces oxygen‑carrying capacity and red‑cell deformability, potentially heightening stroke risk. American Heart Association 146
• Routine prophylactic phlebotomy in patients with compensated erythrocytosis (hematocrit < 54% and no symptoms) is discouraged because of the risk of iron depletion and subsequent cerebrovascular events. American Heart Association 146

Clinical Pitfalls to Avoid

• Do not continue full‑dose testosterone when hematocrit exceeds 54%; this is an absolute indication to withhold therapy. American Heart Association 146
• Do not rely on peak testosterone levels measured 2–5 days after an injection, as supraphysiologic peaks do not reflect average exposure and may lead to inappropriate dose reductions. American Heart Association 146

Strength of evidence: The cited statements are derived from observational and expert‑opinion sources (Circulation 2008; Journal of the American College of Cardiology 2019); specific grading (e.g., Class I, Level A) was not provided in the source material.

Monitoring and Recovery of Iron Stores in Testosterone‑Induced Erythrocytosis

Monitoring Iron Parameters

• Check serum ferritin and transferrin saturation monthly after therapeutic phlebotomy, aiming for a ferritin target of approximately 50–100 µg/L to ensure adequate iron repletion while avoiding excess that could fuel erythropoiesis. 147

Expected Recovery Timeline

• When phlebotomy is discontinued and dietary iron intake is sufficient, ferritin levels are expected to return to the target range within roughly 3–6 months, indicating restoration of iron stores without the need for supplemental iron. 148

Evidence‑Based Guidelines for Testosterone Therapy in Men

Diagnostic Criteria

• Two separate fasting morning total testosterone measurements (8–10 AM) both below 300 ng/dL are required to confirm biochemical hypogonadism. This reduces misclassification due to diurnal variation and assay variability. [149][150]
• Only diminished libido and erectile dysfunction have demonstrated responsiveness to testosterone replacement. Other nonspecific complaints (fatigue, mood changes, “brain fog”) should not trigger therapy even when low testosterone is confirmed. [149][151]

Indications and Expected Benefits

• Testosterone therapy yields a small but statistically significant improvement in sexual function and libido (standardized mean difference ≈ 0.35). The benefit is modest and confined to sexual domains. [149][151]
• Overall quality‑of‑life improvements are modest and limited to sexual function; there is no meaningful enhancement of general well‑being. 151

Lack of Efficacy for Non‑Sexual Symptoms

• In men with confirmed biochemical hypogonadism, testosterone therapy produces little to no clinically meaningful effect on energy, vitality, physical functioning, or cognition. [149][150]151
• Improvement in fatigue or energy is negligible (standardized mean difference ≈ 0.17), well below the threshold for clinical significance. 151
• Symptoms such as fatigue, low energy, depressed mood, poor concentration, and reduced physical strength show minimal correlation with serum testosterone levels and do not improve reliably with replacement therapy. 151
• Even in confirmed hypogonadism, testosterone does not meaningfully improve physical functioning or muscle strength. [149][151]
• No benefit is observed for depressive symptoms (standardized mean difference ≈ ‑0.19, classified as “less‑than‑small”). 151
• Cognition, memory, and overall thinking ability are unaffected by testosterone therapy. [149][151]

Safety and Long‑Term Data

• Long‑term safety data are limited; few randomized trials extend beyond one year of follow‑up. This uncertainty should temper expectations and influence monitoring intensity. 151

Regulatory and Clinical Context

• Age‑related decline in testosterone is not considered a disease requiring treatment. The FDA mandates that testosterone products be labeled for use only in men with low testosterone due to known medical causes, not for age‑related decline. [149][150]
• Approximately 20–30 % of men over 60 have testosterone levels in the low‑normal range, which does not automatically justify therapy. Clinical decision‑making should therefore rely on confirmed hypogonadism and appropriate symptoms. 150
• Uncertainty remains whether nonspecific aging symptoms (decreased energy, muscle‑mass changes, mood disturbances) are attributable to low testosterone or to other comorbidities such as chronic illness or medication effects. [149][150]

Practical Expectations

• When therapy is indicated, clinicians should set realistic expectations: patients can anticipate modest improvements in sexual function only, with no expected gains in energy, mood, or cognitive performance. [149][151]

All statements are derived from peer‑reviewed evidence (Annals of Internal Medicine, 2020) and reflect the current consensus on testosterone therapy.

Evidence‑Based Recommendations for Testosterone Deficiency in Erectile Dysfunction

Diagnosis

• Morning serum total testosterone should be measured between 8 AM and 10 AM; testosterone deficiency is confirmed when two separate measurements are < 300 ng/dL. 152, 153
• After low testosterone is confirmed, LH and FSH must be measured to distinguish primary (elevated LH/FSH) from secondary (low/normal LH/FSH) hypogonadism. 152

Fertility Considerations

• Men who wish to preserve fertility should receive gonadotropin therapy (hCG + FSH) rather than testosterone, because testosterone induces prolonged azoospermia. 154
• In secondary hypogonadism with a desire for fertility, combined hCG and FSH therapy is recommended to restore testosterone levels and support spermatogenesis. 154

Monitoring and Safety

• Hematocrit must be checked at every follow‑up visit; testosterone therapy should be withheld if hematocrit exceeds 54 % and therapeutic phlebotomy considered for high‑risk patients. 154

Combination with Phosphodiesterase‑5 Inhibitors

• PDE5 inhibitors (sildenafil, tadalafil, vardenafil) are first‑line for erectile dysfunction and should be used together with testosterone therapy when testosterone is low. 155, 154
• PDE5 inhibitors are contraindicated in patients taking oral nitrates because of the risk of severe hypotension. 154

Expected Treatment Outcomes

• Testosterone therapy produces a modest but statistically significant improvement in sexual function and libido (standardized mean difference ≈ 0.35) while having little to no effect on physical functioning, energy, mood, or cognition. 154

Diagnostic Pitfalls

• Hypogonadism should not be diagnosed on a single testosterone measurement or on symptoms alone; two morning values < 300 ng/dL plus specific sexual symptoms are required. 152

Severe Hypogonadism – Immediate Evaluation and Management

Diagnostic Workup

• Confirm persistent severe hypogonadism by repeating a morning total testosterone measurement (8–10 AM) on a second occasion; two low values are required before treatment. 156
• Measure serum LH and FSH immediately to differentiate primary (testicular) from secondary (hypothalamic‑pituitary) hypogonadism. 156
• Low or inappropriately normal LH/FSH together with markedly low testosterone indicates secondary hypogonadism and mandates pituitary evaluation. 156
• Elevated LH/FSH indicates primary testicular failure. 156
• When testosterone is <150 ng/dL with low/low‑normal LH/FSH, obtain a pituitary MRI without waiting for prolactin results to rule out non‑functioning adenomas. 156
• Measure serum prolactin; a persistently elevated level (>1.5 × upper limit of normal) suggests prolactinoma and also requires MRI. 156
• Screen for reversible metabolic causes by obtaining fasting glucose and HbA1c to detect diabetes. 156

Baseline Safety Assessment

• Obtain baseline hematocrit/hemoglobin; therapy is contraindicated if hematocrit > 50 % and must be withheld if it rises >54 % during treatment. 156
• In men > 40 years, obtain PSA and perform a digital rectal exam; a PSA > 4.0 ng/mL requires urologic evaluation and a negative prostate biopsy before initiating testosterone. 156
• Conduct a fertility assessment and explicitly confirm desire for future children, because testosterone therapy causes prolonged azoospermia and is contraindicated when fertility is desired. 156

Treatment Selection

• If secondary hypogonadism and fertility is desired: initiate gonadotropin therapy (hCG ± FSH); testosterone replacement is contraindicated because it suppresses spermatogenesis. Refer to reproductive endocrinology for initiation. 156
• If fertility is not desired or primary hypogonadism is confirmed:
  
  • First‑line: transdermal testosterone gel (≈1.6 % concentration, ~40 mg daily) – provides stable serum levels and a lower erythrocytosis risk (≈15 % vs ≈44 % with injectable formulations). 156
  • Alternative: intramuscular testosterone cypionate/enanthate 100–200 mg every 2 weeks – more cost‑effective (≈$150/yr vs ≈$2,100/yr for gel) but carries a higher erythrocytosis risk. 156
• Target mid‑normal serum testosterone concentrations (≈500–600 ng/dL) during monitoring. 156

Expected Treatment Outcomes

• Small but statistically significant improvement in sexual function and libido (standardized mean difference ≈ 0.35). 156
• Little to no benefit for physical functioning, energy, vitality, depressive symptoms, or cognition; set realistic expectations. 156
• Modest favorable changes in metabolic parameters (e.g., insulin resistance, triglycerides, HDL cholesterol) may be observed. 156

Monitoring Protocol

• Initial follow‑up (2–3 months): measure testosterone (mid‑interval for injectables, aiming for 500–600 ng/dL), repeat hematocrit (withhold if > 54 % and consider phlebotomy), re‑check PSA in men > 40 years, and assess clinical response (especially sexual function). 156
• Ongoing monitoring (every 3–6 months during the first year, then annually): repeat testosterone, hematocrit, PSA, and digital rectal exam; refer to urology if PSA rises > 1.0 ng/mL within the first 6 months or > 0.4 ng/mL per year thereafter. 156
• Discontinue testosterone therapy at 12 months if there is no improvement in sexual function to avoid unnecessary exposure. 156

Critical Pitfalls to Avoid

• Do not start testosterone without first measuring LH and FSH, as the distinction between primary and secondary hypogonadism directs therapy and fertility counseling. 156
• Do not initiate testosterone without confirming the patient does not desire future fertility; the treatment can cause prolonged azoospermia. 156
• Do not omit pituitary imaging when testosterone is < 150 ng/dL with low gonadotropins, because treatable pituitary lesions may be missed. 156
• Do not prescribe testosterone for weight loss, general energy enhancement, or athletic performance, as these are not evidence‑based indications. 156

Laboratory Evaluation of Adult Male Hypogonadism

Diagnostic Thresholds

• Obtain two fasting morning total testosterone measurements (8–10 AM) on separate days; biochemical hypogonadism is confirmed only when both values are < 300 ng/dL in adult men. 157

Essential Hormone Panel

• After low total testosterone is confirmed, measure serum luteinizing hormone (LH) to differentiate primary (elevated LH) from secondary (low/normal LH) hypogonadism. 157
• Measure serum follicle‑stimulating hormone (FSH) together with LH to complete the distinction between testicular failure and hypothalamic‑pituitary dysfunction. 157
• Measure serum prolactin in men with low testosterone and low/normal LH‑FSH; if prolactin exceeds 1.5 × the upper limit of normal, repeat the test for confirmation and obtain a pituitary MRI to evaluate for prolactinoma. 157

Free Testosterone Assessment (When Indicated)

• In cases where sex hormone‑binding globulin (SHBG) abnormalities are suspected, determine free testosterone using equilibrium dialysis (gold‑standard) or validated calculated formulas; this helps clarify hypogonadism when total testosterone is borderline. 157

Baseline Safety Assessments Prior to Testosterone Therapy

• Hematocrit/hemoglobin: Document baseline; a hematocrit > 54 % is an absolute contraindication to initiating therapy. 157
• Prostate‑specific antigen (PSA): Required for all men ≥ 40 years; a PSA > 4.0 ng/mL mandates urologic evaluation and a negative prostate biopsy before treatment. 157
• Digital rectal examination: Perform to detect palpable prostate nodules or induration before therapy. 157
• Fasting glucose and HbA1c: Screen for diabetes mellitus as part of the pre‑treatment work‑up. 157

Pituitary Imaging Indications

• Order a pituitary MRI when any of the following are present:

High‑Risk Populations Requiring Testosterone Screening (Even Without Classic Symptoms)

• Men with unexplained anemia.
• Men with decreased bone mineral density.
• Men with diabetes mellitus.
• Men who have undergone recent chemotherapy or testicular radiation.
• Men living with HIV infection.
• Men with chronic narcotic use.
• Men on chronic corticosteroid therapy.
• Men with known pituitary disorders.
• Men presenting with infertility.

Core Diagnostic Algorithm (Key Steps)

Common Pitfalls to Avoid

• Do not diagnose hypogonadism on a single testosterone measurement; two morning values are mandatory. 157
• Do not collect samples outside the 8–10 AM window, as diurnal variation can produce false‑positive results. 157
• Do not omit LH/FSH testing after confirming low testosterone, because the primary vs. secondary distinction guides treatment and fertility counseling. 157
• Do not skip pituitary imaging when testosterone < 150 ng/dL with low gonadotropins, as treatable pituitary lesions may be missed. 157
• Do not rely on direct immunoassays for free testosterone in men with abnormal SHBG; use equilibrium dialysis or calculated free androgen index. 157
• Do not base diagnosis solely on symptoms without biochemical confirmation, given the nonspecific nature of hypogonadal symptoms. 157

Laboratory Consistency

• Because reference ranges vary widely among laboratories, use the same laboratory and assay method for all repeat testosterone measurements to ensure reliable interpretation. 157

Alternatives to Testosterone Replacement When Contraindicated

Fertility Preservation in Men with Secondary Hypogonadism

• Gonadotropin therapy (human chorionic gonadotropin + follicle‑stimulating hormone) is the primary alternative to testosterone replacement for men with secondary hypogonadism who wish to preserve fertility, because it directly stimulates intratesticular testosterone production and spermatogenesis without suppressing the hypothalamic‑pituitary axis. 158, 159
• Gonadotropin therapy is mandatory and exogenous testosterone is absolutely contraindicated in this setting, as testosterone suppresses spermatogenesis and can cause prolonged, potentially irreversible azoospermia. 158, 159
• After 3–6 months of hCG alone, recombinant FSH 75–150 IU subcutaneously 2–3 times weekly should be added if sperm counts remain low. 158
• Combined hCG + FSH therapy provides optimal outcomes for both restoration of serum testosterone to the mid‑normal range and preservation of fertility. 158

Prostate (and Breast) Cancer as an Absolute Contraindication

• Testosterone replacement therapy is absolutely contraindicated in men with a history of breast or prostate cancer. 158, 159
• Current evidence does not include new level 1 studies that would alter this recommendation for men with previously treated or active prostate cancer. 158

Elevated Hematocrit (> 54 %)

• Testosterone therapy must be withheld when hematocrit exceeds 54 %; therapy should be resumed only after hematocrit falls below 52 %. 158

Obstructive Sleep Apnea (OSA) Considerations

• Recent level 1 evidence indicates that untreated OSA and severe lower urinary tract symptoms are not absolute contraindications to testosterone therapy, although severe untreated OSA remains a relative contraindication requiring careful assessment. 158, 159

Evaluation and Management of Testosterone Deficiency in Middle‑Aged Men

1. Diagnostic Criteria

• Biochemical confirmation requires two separate fasting morning (8–10 AM) total testosterone measurements < 300 ng/dL to establish hypogonadism. The European Association of Urology (EAU) recommends this dual‑test approach to avoid misdiagnosis due to diurnal variation. 160

• Primary vs. secondary differentiation: after low testosterone is confirmed, serum LH and FSH should be measured.

  • Elevated LH/FSH → primary (testicular) hypogonadism.
  • Low or inappropriately normal LH/FSH → secondary (hypothalamic‑pituitary) hypogonadism. The EAU stresses that this distinction guides therapy and fertility counseling. 160

• Free testosterone assessment is advised when total testosterone lies in the gray zone (≈ 231–346 ng/dL). Free testosterone can be measured by equilibrium dialysis or estimated using the free androgen index (total testosterone ÷ SHBG × 100). This helps identify functional hypogonadism, especially in obese patients. 160

2. Etiology – Secondary (Hypothalamic‑Pituitary) Causes

Metabolic and Lifestyle Factors

• Obesity is the most common reversible cause of secondary hypogonadism in men aged 40–70. Excess adipose tissue increases aromatization of testosterone to estradiol, which exerts negative feedback on the pituitary and suppresses LH secretion. 160

• Metabolic syndrome and type 2 diabetes are strongly linked to testosterone deficiency; insulin resistance directly impairs testicular testosterone synthesis and disrupts hypothalamic‑pituitary signaling. 160

• Smoking raises SHBG levels, resulting in lower free testosterone concentrations. 160

Medication‑Induced Suppression

• Agents that suppress the hypothalamic‑pituitary axis (causing secondary hypogonadism) include chronic glucocorticoids, chronic opioid/narcotic use, exogenous testosterone or anabolic androgenic steroids, and growth‑hormone therapy. The EAU recommends reviewing the medication list for any of these agents. 160

• Drugs that increase SHBG (producing functional hypogonadism) comprise anticonvulsants, estrogen therapy, and thyroid hormone supplementation. Elevated SHBG reduces bioavailable testosterone. 160

Chronic Medical Conditions

• Non‑alcoholic fatty liver disease (NAFLD), early‑stage chronic kidney disease, subclinical hypothyroidism, obstructive sleep apnea, and chronic inflammatory states are associated with secondary hypogonadism and should be screened for in men with low testosterone. 160

Pituitary Disorders

• Hyperprolactinemia (e.g., prolactinoma) suppresses GnRH pulsatility, leading to reduced LH/FSH secretion and secondary hypogonadism. 160

• Non‑functioning pituitary adenomas can cause mass effect on the hypothalamic‑pituitary axis, resulting in secondary hypogonadism even without hormonal hypersecretion. 160

3. Etiology – Primary (Testicular) Causes

• Klinefelter syndrome (47,XXY) is the most common congenital cause of primary hypogonadism and may present in adulthood with subtle features. Karyotype analysis is advised when clinical suspicion exists. 160

• Testicular injury, torsion, infection, or a history of cryptorchidism can lead to irreversible testicular failure. A thorough genital history is essential. 160

• Chemotherapy or radiation exposure to the testes produces dose‑dependent damage and primary hypogonadism. 160

• Systemic diseases such as HIV/AIDS and hepatic cirrhosis can cause primary or secondary hypogonadism; cirrhosis elevates SHBG and impairs testosterone production. 160

4. Age‑Related Decline

• Testosterone levels decline approximately 1–2 % per year after age 40. In a healthy 46‑year‑old, this gradual decline rarely produces symptomatic hypogonadism; reversible metabolic causes are far more common and should be investigated first. 160

5. Recommended Diagnostic Work‑up for a 46‑Year‑Old Male

6. Management Considerations

• Secondary hypogonadism can often be treated with gonadotropin therapy (hCG ± FSH) to restore both testosterone production and fertility, whereas primary hypogonadism generally requires testosterone replacement, which permanently suppresses spermatogenesis. 160

• Fertility counseling must precede any testosterone replacement because exogenous testosterone induces prolonged azoospermia. 160

7. Common Pitfalls (EAU Recommendations)

• Avoid diagnosing on a single testosterone value; require two separate morning measurements. 160

• Never skip LH/FSH testing after confirming low testosterone; the primary/secondary distinction is essential for appropriate therapy. 160

• Do not attribute low testosterone solely to age in men under 50; prioritize evaluation for obesity, diabetes, medication effects, and other reversible factors. 160

• Medication review is critical; chronic opioids, glucocorticoids, and anabolic steroids are frequently missed causes of secondary hypogonadism. 160

• Address fertility goals before initiating testosterone therapy to prevent irreversible infertility. 160